busulfan and Hematologic Malignancies studies

Research Excerpts

Excerpt	Relevance	Reference
" Patients with hematologic malignancies for whom limited long-term survival was expected with standard therapy were administered an outpatient conditioning regimen of busulfan 3."	9.20	Nonmyeloablative allogeneic hematopoietic stem cell transplant for the treatment of patients with hematologic malignancies using busulfan, fludarabine, and total body irradiation conditioning is effective in an elderly and infirm population. ( Avraham, GP; Brammer, JE; Curtin, P; Frires, R; Gajewski, J; Hayes-Lattin, B; Kovacsovics, T; Leis, JF; Maziarz, RT; Meyers, G; Nemecek, E; Palmbach, G; Slater, S; Stentz, A; Subbiah, N, 2015)
"The primary aim of this study was to evaluate the efficacy of palonosetron combined with dexamethasone in the prevention of vomiting, and especially nausea, in patients receiving allogeneic stem cell transplantation."	9.19	Palonosetron and dexamethasone for the prevention of nausea and vomiting in patients receiving allogeneic hematopoietic stem cell transplantation. ( Bai, LY; Chiu, CF; Hsieh, CY; Liao, YM; Lin, CC; Lin, CY; Lin, PH; Lo, WC; Yeh, SP, 2014)
"The purpose of this study was to evaluate the effect of oral zinc sulfate in the prevention of chemotherapy-induced mucositis in patients undergoing hematopoietic stem-cell transplantation (HSCT)."	9.16	The effect of zinc sulfate in the prevention of high-dose chemotherapy-induced mucositis: a double-blind, randomized, placebo-controlled study. ( Alimoghaddam, K; Ghavamzadeh, A; Hadjibabaie, M; Hayatshahi, A; Iravani, M; Javadi, MR; Khoee, SH; Mansouri, A; Shamshiri, AR, 2012)
"In this prospective study 60 patients of median age 46 (range: 5-60 years), with acute myelogenous leukemia (AML; n = 44), acute lymphoblastic leukemia (ALL; n = 3), or myelodysplastic syndrome (MDS; n = 13) were conditioned for allogeneic hematopoietic cell transplantation with a treosulfan/fludarabine (Flu) combination."	9.15	Conditioning with treosulfan and fludarabine followed by allogeneic hematopoietic cell transplantation for high-risk hematologic malignancies. ( Appelbaum, FR; Bedalov, A; Deeg, HJ; Doney, KC; Flowers, ME; Guthrie, KA; Hilger, RA; Kovacsovics, TJ; Maziarz, RT; Nemecek, ER; Pagel, JM; Sanders, JE; Scott, BL; Sickle, EJ; Sorror, ML; Witherspoon, R; Wood, BL; Woolfrey, AE, 2011)
"We assessed the combination of sirolimus, tacrolimus, and low-dose methotrexate as acute graft-versus-host disease (aGVHD) prophylaxis after reduced-intensity conditioning (RIC) allogeneic peripheral blood stem cell (PBSC) transplantation from matched related (MRD, n = 46) and unrelated (URD, n = 45) donors."	9.13	Sirolimus, tacrolimus, and low-dose methotrexate as graft-versus-host disease prophylaxis in related and unrelated donor reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation. ( Alyea, EP; Antin, JH; Cutler, C; Ho, V; Kim, HT; Li, S; Soiffer, RJ, 2008)
" The dose of a widely studied agent in this setting, busulfan, can be adjusted based on area under the curve (AUC); however, choice of actual body weight (ABW) versus adjusted body weight (DBW) weight to calculate the initial dose may be critical in attaining goal AUC."	7.81	Busulfan dosing (Q6 or Q24) with adjusted or actual body weight, does it matter? ( Awan, FT; Clemmons, AB; DeRemer, DL; Evans, S, 2015)
"We aim to evaluate the clinical efficacy of a modified busulfan and cyclophosphamide (BU/CY) conditioning regimen for allogeneic hematopoietic stem cell transplantation (allo-HSCT) in the treatment of hematologic malignancies."	7.80	Modified busulfan and cyclophosphamide conditioning regimen for allogeneic hematopoietic stem cell transplantation in the treatment of patients with hematologic malignancies. ( Liu, W; Mao, XF; Wan, DM; Zhao, XF, 2014)
"Fifty-six patients with various hematologic malignancies who were not eligible for standard conditioning were treated with one of three doses: 10 g/m(2), 12 g/m(2), or 14 g/m(2) of intravenous treosulfan, which was administered on days -6 to -4 combined with fludarabine 30 mg/m(2) on days -6 to -2."	7.76	Allogeneic hematopoietic stem-cell transplantation in patients with hematologic malignancies after dose-escalated treosulfan/fludarabine conditioning. ( Aschan, J; Baumgart, J; Blau, IW; Casper, J; Freund, M; Giebel, S; Hilgendorf, I; Holowiecki, J; Knauf, W; Kröger, N; Mylius, HA; Pichlmeier, U; Ruutu, T; Schäfer-Eckart, K; Volin, L; Wandt, H; Wolff, D; Zander, AR, 2010)
"To analyze the results of idarubicin (IDA)- versus etoposide (VP16)-intensified myeloablative conditioning regimen in allogeneic hematopoietic stem cell transplantation (allo-SCT) for high-risk acute leukemia."	7.75	A comparative study of outcomes of idarubicin- and etoposide-intensified conditioning regimens for allogeneic peripheral blood stem cell transplantation in patients with high-risk acute leukemia. ( Chen, ZC; Li, L; Li, QB; Xia, LH; You, Y; Zou, P, 2009)
"We investigated the pharmacokinetics (PK) of a recently approved intravenous busulfan (IVBU) formulation as a part of the preparative regimen in 20 children with advanced hematologic malignancies undergoing allogeneic hematopoietic stem cell transplantation."	7.72	Pharmacokinetics and individualized dose adjustment of intravenous busulfan in children with advanced hematologic malignancies undergoing allogeneic stem cell transplantation. ( Andersson, B; Chan, KW; Choroszy, M; Madden, T; Mullen, CA; Nguyen, J; Petropoulos, D; Tran, H; Webb, SK; Worth, L, 2004)
"We investigated whether adjusting the oral busulfan (BU) dosage on the basis of early pharmacokinetic data to achieve a targeted drug exposure could reduce transplant-related complications in children with advanced hematologic malignancies."	7.70	Individualizing high-dose oral busulfan: prospective dose adjustment in a pediatric population undergoing allogeneic stem cell transplantation for advanced hematologic malignancies. ( Chan, KW; Choroszy, M; Danielson, M; Felix, EA; Madden, T; Petropoulos, D; Przepiorka, D; Sprigg-Saenz, HA; Tran, HT; Worth, LL, 2000)
" On the basis of the dosing guidelines and schedule outlined in this study, our data suggest that administration of IV Bu 3."	6.71	Dose modification protocol using intravenous busulfan (Busulfex) and cyclophosphamide followed by autologous or allogeneic peripheral blood stem cell transplantation in patients with hematologic malignancies. ( Abbott, BL; Abhyankar, S; Bechtel, T; Copelan, EA; Day, SD; Leather, HL; McGuirk, JP; Reed, MD; Williams, CB; Wingard, JR, 2004)
"Busulfan (Bu) is an alkylating agent routinely used for conditioning regimens before allogeneic stem cell transplantation (allo-SCT)."	5.62	Feasibility and Efficacy of a Pharmacokinetics-Guided Busulfan Conditioning Regimen for Allogeneic Stem Cell Transplantation with Post-Transplantation Cyclophosphamide as Graft-versus-Host Disease Prophylaxis in Adult Patients with Hematologic Malignancie ( Bartoli, A; Bramanti, S; Castagna, L; De Gregori, S; De Philippis, C; Giordano, L; Mannina, D; Mariotti, J; Pieri, G; Roperti, M; Sarina, B; Valli, V, 2021)
"Busulfan has a narrow therapeutic index and its concentration was found to correlate with VOD."	5.56	Busulfan clearance does not predict the development of hepatic veno-occlusive disease in patients undergoing hematopoietic stem cell transplantation. ( Al-Huneini, M; Al-Khabori, M; Al-Rawas, A; Al-Za'abi, M; Dennison, D; Salman, B, 2020)
"Factors independently associated with delayed puberty were extensive chronic GVHD (P = ."	5.56	Pubertal outcomes of children transplanted with allogeneic stem cells after myeloablative total body irradiation or busulfan: Influence of age and sex is confirmed, while a role of chronic graft-versus-host disease in delayed puberty onset is revealed. ( Dalle, JH; Lebon Labich, B; Leheup, B; Pochon, C; Weinhard, S; Wiedemann, A, 2020)
"Modified Bu/Flu as a new RIC regimen is well tolerated and safe for patients who need allogeneic hematopoietic stem cell transplantation, especially in older patients and/or patients with severe comorbidities."	5.39	[The efficacy and safety of modified busulfan/fludarabine conditioning regimen in elderly or drug-intolerable patients with hematologic malignancies]. ( Chen, H; Fu, HX; Huang, XJ; Liu, DH; Liu, KY; Sun, YQ; Tang, FF; Wang, FR; Wang, Y; Xu, LP, 2013)
"The clinical advantage of pharmacokinetic (PK)-directed-based dosing on intravenous (i."	5.38	Pharmacokinetic-directed high-dose busulfan combined with cyclophosphamide and etoposide results in predictable drug levels and durable long-term survival in lymphoma patients undergoing autologous stem cell transplantation. ( Ali, Z; Dada, MO; Flowers, CR; Graiser, M; Hutcherson, DA; McMillan, S; Waller, EK; Zhang, H, 2012)
" Graft-versus-host disease (GVHD) prophylaxis consisted of cyclosporine and mycophenolate for all patients, associated with ATG in 39 patients (76."	5.30	Thiotepa, Busulfan, and Fludarabine Conditioning Regimen in T Cell-Replete HLA-Haploidentical Hematopoietic Stem Cell Transplantation. ( Adaeva, R; Banet, A; Bastos, J; Battipaglia, G; Belhocine, R; Brissot, E; de Wyngaert, ZV; Duléry, R; Giannotti, F; Isnard, F; Lapusan, S; Ledraa, T; Legrand, O; Malard, F; Médiavilla, C; Mohty, M; Paviglianiti, A; Rubio, MT; Ruggeri, A; Sestili, S; Vekhoff, A, 2019)
" Administration of phenytoin or newer alternative antiepileptic medications (AEMs) prevents seizures caused by BU."	5.30	Association of Antiepileptic Medications with Outcomes after Allogeneic Hematopoietic Cell Transplantation with Busulfan/Cyclophosphamide Conditioning. ( Aljurf, M; Beitinjaneh, A; Bo-Subait, K; Bubalo, J; Cahn, JY; Cerny, J; Chhabra, S; Cumpston, A; Dupuis, LL; Krem, MM; Lazarus, HM; Marks, DI; Martin, PJ; Maziarz, RT; McCune, JS; Mineishi, S; Norkin, M; Pasquini, M; Prestidge, T; Wang, T, 2019)
" Patients with hematologic malignancies for whom limited long-term survival was expected with standard therapy were administered an outpatient conditioning regimen of busulfan 3."	5.20	Nonmyeloablative allogeneic hematopoietic stem cell transplant for the treatment of patients with hematologic malignancies using busulfan, fludarabine, and total body irradiation conditioning is effective in an elderly and infirm population. ( Avraham, GP; Brammer, JE; Curtin, P; Frires, R; Gajewski, J; Hayes-Lattin, B; Kovacsovics, T; Leis, JF; Maziarz, RT; Meyers, G; Nemecek, E; Palmbach, G; Slater, S; Stentz, A; Subbiah, N, 2015)
"The primary aim of this study was to evaluate the efficacy of palonosetron combined with dexamethasone in the prevention of vomiting, and especially nausea, in patients receiving allogeneic stem cell transplantation."	5.19	Palonosetron and dexamethasone for the prevention of nausea and vomiting in patients receiving allogeneic hematopoietic stem cell transplantation. ( Bai, LY; Chiu, CF; Hsieh, CY; Liao, YM; Lin, CC; Lin, CY; Lin, PH; Lo, WC; Yeh, SP, 2014)
"Fifty patients with high-risk hematologic malignancies, underwent an unmanipulated haploidentical bone marrow transplantation (BMT), followed by posttransplantation high-dose cyclophosphamide (PT-CY): the myeloablative (MA) conditioning consisted of thiotepa, busulfan, fludarabine (n = 35), or total body irradiation (TBI), fludarabine (n = 15)."	5.17	Unmanipulated haploidentical bone marrow transplantation and posttransplantation cyclophosphamide for hematologic malignancies after myeloablative conditioning. ( Bacigalupo, A; Ballerini, F; Bregante, S; Di Grazia, C; Dominietto, A; Geroldi, S; Ghiso, A; Gualandi, F; Lamparelli, T; Luchetti, S; Miglino, M; Raiola, AM; Van Lint, MT; Varaldo, R, 2013)
"The purpose of this study was to evaluate the effect of oral zinc sulfate in the prevention of chemotherapy-induced mucositis in patients undergoing hematopoietic stem-cell transplantation (HSCT)."	5.16	The effect of zinc sulfate in the prevention of high-dose chemotherapy-induced mucositis: a double-blind, randomized, placebo-controlled study. ( Alimoghaddam, K; Ghavamzadeh, A; Hadjibabaie, M; Hayatshahi, A; Iravani, M; Javadi, MR; Khoee, SH; Mansouri, A; Shamshiri, AR, 2012)
"Sixteen patients diagnosed with various hematologic malignancies participated in a phase II study evaluating the addition of rabbit antithymocyte globulin (rATG, Thymoglobulin(®)) to the hematopoietic cell transplant (HCT) conditioning regimen of IV fludarabine monophosphate (fludarabine) and targeted intravenous (IV) busulfan (fludarabine/(T)busulfan)."	5.16	A pilot pharmacologic biomarker study of busulfan and fludarabine in hematopoietic cell transplant recipients. ( Deeg, HJ; Furlong, T; Heimfeld, S; McCune, JS; O'Donnell, PV; Storer, B; Wang, J; Woodahl, EL, 2012)
"In this prospective study 60 patients of median age 46 (range: 5-60 years), with acute myelogenous leukemia (AML; n = 44), acute lymphoblastic leukemia (ALL; n = 3), or myelodysplastic syndrome (MDS; n = 13) were conditioned for allogeneic hematopoietic cell transplantation with a treosulfan/fludarabine (Flu) combination."	5.15	Conditioning with treosulfan and fludarabine followed by allogeneic hematopoietic cell transplantation for high-risk hematologic malignancies. ( Appelbaum, FR; Bedalov, A; Deeg, HJ; Doney, KC; Flowers, ME; Guthrie, KA; Hilger, RA; Kovacsovics, TJ; Maziarz, RT; Nemecek, ER; Pagel, JM; Sanders, JE; Scott, BL; Sickle, EJ; Sorror, ML; Witherspoon, R; Wood, BL; Woolfrey, AE, 2011)
"We assessed the combination of sirolimus, tacrolimus, and low-dose methotrexate as acute graft-versus-host disease (aGVHD) prophylaxis after reduced-intensity conditioning (RIC) allogeneic peripheral blood stem cell (PBSC) transplantation from matched related (MRD, n = 46) and unrelated (URD, n = 45) donors."	5.13	Sirolimus, tacrolimus, and low-dose methotrexate as graft-versus-host disease prophylaxis in related and unrelated donor reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation. ( Alyea, EP; Antin, JH; Cutler, C; Ho, V; Kim, HT; Li, S; Soiffer, RJ, 2008)
"In the current study, we have analyzed the efficacy of cyclosporine A (CSA) plus mycophenolate mofetil (MMF) as graft-versus-host disease (GVHD) prophylaxis in the fludarabine plus melphalan or busulfan reduced intensity regimen (RIC) setting in a series of 44 patients receiving allogeneic transplantation from an unrelated donor."	5.13	Reduced-intensity conditioning allogeneic transplantation from unrelated donors: evaluation of mycophenolate mofetil plus cyclosporin A as graft-versus-host disease prophylaxis. ( Caballero, D; Calvo, MV; de la Cámara, R; de Oteiza, JP; Heras, I; Martino, R; Pérez-Simón, JA; Rebollo, N; San Miguel, JF; Sierra, J; Valcarcel, D, 2008)
" We developed an at-home ASCT program in which prophylactic ceftriaxone and treatment of febrile neutropenia with piperacillin and tazobactam was introduced to minimize the readmission rate."	5.12	Case-control comparison of at-home to total hospital care for autologous stem-cell transplantation for hematologic malignancies. ( Carreras, E; Fernández-Avilés, F; Gallego, C; García, L; Gaya, A; González, M; Granell, M; Hernando, A; Martínez, C; Montserrat, E; Ramiro, L; Rovira, M; Segura, S; Urbano-Ispizua, A; Valverde, M, 2006)
" Using conditioning consisting of fludarabine, busulfan, and anti-T-lymphocyte globulin and GVHD prophylaxis consisting of tacrolimus and methylprednisolone (1 mg/kg/day), 26 patients who had hematologic malignancies in an advanced stage or with a poor prognosis underwent transplantation using peripheral blood stem cells from an HLA-haploidentical donor (2-3 antigen mismatches in the graft-versus-host [GVH] direction) without T-cell depletion."	5.12	Unmanipulated HLA 2-3 antigen-mismatched (haploidentical) stem cell transplantation using nonmyeloablative conditioning. ( Fujioka, T; Hasei, H; Ikegame, K; Inoue, T; Kaida, K; Kawakami, M; Kawase, I; Kim, EH; Masuda, T; Ogawa, H; Taniguchi, Y; Yoshihara, S, 2006)
" Cyclosporine alone or cyclosporine with short-term methotrexate was randomized for graft-versus-host disease prophylaxis."	5.12	Prospective phase II trial to evaluate the complications and kinetics of chimerism induction following allogeneic hematopoietic stem cell transplantation with fludarabine and busulfan. ( Hara, M; Hino, M; Hori, A; Kami, M; Kanda, Y; Kim, SW; Mineishi, S; Mori, S; Ohashi, Y; Saito, AM; Suzuki, R; Takami, A; Takaue, Y; Takemoto, Y; Taniguchi, S; Yamaguchi, M; Yoshida, T, 2007)
"Fifteen heavily pretreated high-risk patients (age 25-66, median 42 years) with hematologic malignancies were conditioned with busulfan alone, 4mg/kg/day for 2, 3, or 4 consecutive days."	5.11	Successful engraftment following allogeneic stem cell transplantation in very high-risk patients with busulfan as a single agent. ( Ackerstein, A; Bitan, M; Elad, S; Or, R; Resnick, IB; Samuel, S; Shapira, MY; Slavin, S, 2005)
" Between December 1997 and March 2000, 40 patients, aged 21 to 67 years (median 51), with hematologic malignancies underwent nonmyeloablative allografts after either 2 Gy total body irradiation alone (n = 30) or 2 Gy total body irradiation preceded by fludarabine 30 mg/m(2)/d on days -4, -3, and -2 (n = 10)."	5.09	Decreased transfusion requirements for patients receiving nonmyeloablative compared with conventional peripheral blood stem cell transplants from HLA-identical siblings. ( Bensinger, WI; Gooley, T; Maloney, DG; Sandmaier, BM; Storb, R; Weissinger, F, 2001)
" Cyclosporine- cyclophosphamide-mycophenolate mofetil was the most widely used graft-versus-host disease prophylaxis regimen."	4.31	A single-center experience of haploidentical stem cell transplantation in hematological malignancies. ( Akdemir, NB; Büyükaşık, Y; Demiroğlu, H; Göker, H; Haznedaroğlu, İC; Karakulak, EA; Malkan, ÜY; Özcebe, Oİ; Sayınalp, N; Tekin, F, 2023)
"The clinical data of 190 patients with hematological malignancies undergoing sUCBT between April 2000 and December 2013 at Department of Hematology, Anhui Provincial Hospital were retrospectively analyzed, of whom 156 received IMCR without ATG (IMCR group), including 79 patient receiving total body irradiation (TBI)/cytosine arabinoside (Ara-C)/cyclophosphamide (CY) regime, 47 receiving fludarabine (Flu)/busulfan (Bu)/CY regime, and 30 receiving Ara-C/Bu/CY regime, and all of the 156 received a combination of cyclosporine A (CsA) and mycophelonate mofetil (MMF) for the prophylaxis of graft-versus-host disease (GVHD); the remaining 34 patients received MCR (MCR group), 30 patients receiving Bu/CY regime, and 4 receiving TBI/CY regime, all using CsA/MMF±ATG or methotrexate (MTX) for the prophylaxis of GVHD."	3.83	[Comparison of intensified myeloablative conditioning regime without antithymocytic globulin (ATG) with myeloablative conditioning regime for single-unit unrelated umbilical cord blood transplantation in hematological malignancies]. ( Ding, KY; Geng, LQ; Han, YS; Liu, HL; Liu, X; Sun, ZM; Tang, BL; Tong, J; Wan, X; Wang, XB; Wang, ZY; Wu, JS; Wu, Y; Yang, HZ; Yao, W; Zhang, L; Zhang, XH; Zheng, CC; Zhu, WW; Zhu, XY, 2016)
" Pharmacokinetic parameters were evaluated following first dose using a two-compartment disposition model."	3.83	Pharmacokinetics of high-dose i.v. treosulfan in children undergoing treosulfan-based preparative regimen for allogeneic haematopoietic SCT. ( Grund, G; Główka, FK; Karaźniewicz-Łada, M; Wachowiak, J; Wróbel, T, 2008)
" The dose of a widely studied agent in this setting, busulfan, can be adjusted based on area under the curve (AUC); however, choice of actual body weight (ABW) versus adjusted body weight (DBW) weight to calculate the initial dose may be critical in attaining goal AUC."	3.81	Busulfan dosing (Q6 or Q24) with adjusted or actual body weight, does it matter? ( Awan, FT; Clemmons, AB; DeRemer, DL; Evans, S, 2015)
"We aim to evaluate the clinical efficacy of a modified busulfan and cyclophosphamide (BU/CY) conditioning regimen for allogeneic hematopoietic stem cell transplantation (allo-HSCT) in the treatment of hematologic malignancies."	3.80	Modified busulfan and cyclophosphamide conditioning regimen for allogeneic hematopoietic stem cell transplantation in the treatment of patients with hematologic malignancies. ( Liu, W; Mao, XF; Wan, DM; Zhao, XF, 2014)
"Conditioning regimen including fludarabine, intravenous busulfan (Bx), and 5 mg/kg total dose of rabbit antithymocyte globulin (r-ATG) (FBx-ATG) results in low incidence of graft-versus-host disease (GVHD) and non-relapse mortality (NRM) after allogeneic hematopoietic stem cell transplantation (Allo-HSCT) from HLA-matched related or unrelated donors (MUD)."	3.80	A conditioning platform based on fludarabine, busulfan, and 2 days of rabbit antithymocyte globulin results in promising results in patients undergoing allogeneic transplantation from both matched and mismatched unrelated donor. ( Blaise, D; Bouabdallah, R; Calmels, B; Castagna, L; Chabannon, C; Coso, D; Crocchiolo, R; D'Incan, E; Devillier, R; El-Cheikh, J; Etienne, A; Fürst, S; Granata, A; Harbi, S; Lemarie, C; Picard, C; Schiano, JM; Stoppa, AM; Vey, N, 2014)
"Fifty-six patients with various hematologic malignancies who were not eligible for standard conditioning were treated with one of three doses: 10 g/m(2), 12 g/m(2), or 14 g/m(2) of intravenous treosulfan, which was administered on days -6 to -4 combined with fludarabine 30 mg/m(2) on days -6 to -2."	3.76	Allogeneic hematopoietic stem-cell transplantation in patients with hematologic malignancies after dose-escalated treosulfan/fludarabine conditioning. ( Aschan, J; Baumgart, J; Blau, IW; Casper, J; Freund, M; Giebel, S; Hilgendorf, I; Holowiecki, J; Knauf, W; Kröger, N; Mylius, HA; Pichlmeier, U; Ruutu, T; Schäfer-Eckart, K; Volin, L; Wandt, H; Wolff, D; Zander, AR, 2010)
"To analyze the results of idarubicin (IDA)- versus etoposide (VP16)-intensified myeloablative conditioning regimen in allogeneic hematopoietic stem cell transplantation (allo-SCT) for high-risk acute leukemia."	3.75	A comparative study of outcomes of idarubicin- and etoposide-intensified conditioning regimens for allogeneic peripheral blood stem cell transplantation in patients with high-risk acute leukemia. ( Chen, ZC; Li, L; Li, QB; Xia, LH; You, Y; Zou, P, 2009)
"We have reported a lower incidence of acute graft-versus-host disease (aGVHD) with a novel conditioning regimen using low-dose rabbit antithymocyte globulin (ATG; Thymoglobulin [TG]) with fludarabine and intravenous busulfan (FluBuTG)."	3.74	Outcomes following HSCT using fludarabine, busulfan, and thymoglobulin: a matched comparison to allogeneic transplants conditioned with busulfan and cyclophosphamide. ( Agovi, MA; Bacigalupo, A; Bahlis, NJ; Ballen, K; Bredeson, CN; Brown, C; Chaudhry, MA; Horowitz, MM; Kurian, S; Muehlenbien, CE; Quinlan, D; Rizzo, JD; Russell, JA; Savoie, L; Stewart, DA; Zhang, MJ, 2008)
" In this report, we analyzed the outcome of 101 high-risk patients (70 hematologic and 31 nonhematologic malignancies) who received an HLA-identical sibling allo-SCT after RIC, including fludarabine, busulfan, and antithymocyte globulin (ATG)."	3.72	Graft-versus-host disease following allogeneic transplantation from HLA-identical sibling with antithymocyte globulin-based reduced-intensity preparative regimen. ( Bay, JO; Bilger, K; Blaise, D; Chabannon, C; Choufi, B; Coso, D; Faucher, C; Maraninchi, D; Mohty, M; Stoppa, AM; Tournilhac, O; Vey, N; Viens, P, 2003)
"We investigated the pharmacokinetics (PK) of a recently approved intravenous busulfan (IVBU) formulation as a part of the preparative regimen in 20 children with advanced hematologic malignancies undergoing allogeneic hematopoietic stem cell transplantation."	3.72	Pharmacokinetics and individualized dose adjustment of intravenous busulfan in children with advanced hematologic malignancies undergoing allogeneic stem cell transplantation. ( Andersson, B; Chan, KW; Choroszy, M; Madden, T; Mullen, CA; Nguyen, J; Petropoulos, D; Tran, H; Webb, SK; Worth, L, 2004)
"We investigated whether adjusting the oral busulfan (BU) dosage on the basis of early pharmacokinetic data to achieve a targeted drug exposure could reduce transplant-related complications in children with advanced hematologic malignancies."	3.70	Individualizing high-dose oral busulfan: prospective dose adjustment in a pediatric population undergoing allogeneic stem cell transplantation for advanced hematologic malignancies. ( Chan, KW; Choroszy, M; Danielson, M; Felix, EA; Madden, T; Petropoulos, D; Przepiorka, D; Sprigg-Saenz, HA; Tran, HT; Worth, LL, 2000)
"Twenty-five patients with hematologic malignancies were treated with busulfan (16 mg/kg) and cyclophosphamide (50 mg/kg x 3 days) as conditioning for bone marrow transplantation using marrow from serologically matched, DR locus genotypically identical unrelated donors."	3.69	Unrelated donor bone marrow transplantation without T cell depletion using a chemotherapy only condition regimen. Low incidence of failed engraftment and severe acute GVHD. ( Brodsky, I; Bulova, S; Crilley, P; Marks, DI; Styler, MJ; Topolsky, D, 1996)
"Although exposure-directed busulfan (BU) dosing can improve allogeneic hematopoietic stem cell transplantation outcomes, there is still large variability in BU exposure with test dose alone due to changes in BU clearance caused by drug interactions."	3.30	Effects of combined test dose and therapeutic drug monitoring strategy in exposure-directed busulfan. ( Akasaka, T; Anzai, N; Arai, Y; Arima, N; Iemura, T; Ikeda, T; Imada, K; Ishikawa, T; Itoh, M; Kanda, J; Kitano, T; Kitawaki, T; Kondo, T; Maeda, T; Matsumoto, K; Moriguchi, T; Nohgawa, M; Takaori-Kondo, A; Takeoka, T; Ueda, A; Ueda, Y; Watanabe, M; Yago, K; Yamashita, K; Yonezawa, A, 2023)
"Forty-three patients with high-risk hematologic malignancies (median age, 43 years) were enrolled between December 2011 and September 2013."	2.82	Posttransplantation cyclophosphamide for prevention of graft-versus-host disease after HLA-matched mobilized blood cell transplantation. ( Appelbaum, FR; Carpenter, PA; Flowers, ME; Furlong, T; Martin, PJ; McCune, JS; Mielcarek, M; O'Donnell, PV; Storb, R; Storer, BE, 2016)
" The estimated Cmax was 1."	2.80	Once-daily i.v. BU-based conditioning regimen before allogeneic hematopoietic SCT: a study of influence of GST gene polymorphisms on BU pharmacokinetics and clinical outcomes in Chinese patients. ( Xiao, Y; Yin, J; Zhang, YC; Zheng, H, 2015)
"Fifty-four patients with advanced hematologic malignancies were enrolled on this study."	2.80	Phase I/II Trial of Dose-Escalated Busulfan Delivered by Prolonged Continuous Infusion in Allogeneic Transplant Patients. ( Armistead, P; Chung, Y; Coghill, J; Comeau, T; Gabriel, D; Ivanova, A; Rao, K; Sarantopoulos, S; Serody, J; Shea, TC; Sheets, J; Walko, C; Wood, W, 2015)
" We conducted a phase I/II controlled, adoptive, randomized study to determine the optimal dosing schedule of i."	2.78	Dose intensification of busulfan in the preparative regimen is associated with improved survival: a phase I/II controlled, randomized study. ( Anderlini, P; Bassett, R; Champlin, R; de Lima, M; Ganesan, P; Giralt, S; Kebriaei, P; Khouri, I; Parmar, S; Rondon, G; Thall, P, 2013)
"Busulfan clearance was not associated with sex or age, but was associated with the day of dosing and conditioning regimen (P = ."	2.77	Accurate targeting of daily intravenous busulfan with 8-hour blood sampling in hospitalized adult hematopoietic cell transplant recipients. ( Blough, DK; Deeg, HJ; McCune, JS; McDonald, GB; O'Donnell, PV; Pawlikowski, MA; Rezvani, A; Yeh, RF, 2012)
" However, when both the test and the treatment doses were administered at the same infusion rate, clearance of the drug between the 2 dosing days was equivalent."	2.77	Development and validation of a test dose strategy for once-daily i.v. busulfan: importance of fixed infusion rate dosing. ( Bahlis, NJ; Brown, CB; Chaudhry, MA; Daly, A; Duggan, P; Geddes, M; Kangarloo, SB; Magliocco, AM; Naveed, F; Ng, ES; Quinlan, D; Russell, JA; Savoie, ML; Shafey, M; Stewart, DA; Storek, J; Wu, J; Yang, M; Yue, P; Zacarias, N, 2012)
"busulfan doses 1 and 2 were 170 mg/m(2)/day, then doses 3 and 4 were adjusted based on first-dose pharmacokinetic modeling to achieve an average daily AUC of 6,000 μM-min."	2.77	Maximally tolerated busulfan systemic exposure in combination with fludarabine as conditioning before allogeneic hematopoietic cell transplantation. ( Anasetti, C; Ayala, E; Fernandez, HF; Field, TL; Kharfan-Dabaja, MA; Kim, J; Perez, LE; Perkins, JB; Pidala, JA; Sullivan, DM; Tomblyn, MR, 2012)
"busulfan was similar between patients with GSTA1∗A/∗A and GSTM1/GSTT1 double-null genotypes and those with GSTA1∗A/∗B and GSTM1/GSTT1 double-positive genotypes."	2.76	Influence of GST gene polymorphisms on the clearance of intravenous busulfan in adult patients undergoing hematopoietic cell transplantation. ( Bae, KS; Choi, Y; Han, SB; Hur, EH; Kim, DY; Kim, SD; Lee, JH; Lee, KH; Lim, HS; Lim, SN; Noh, GJ; Yun, SC, 2011)
" A dose-response relationship between busulfan exposure and outcome is known."	2.75	Phase I study of dose-escalated busulfan with fludarabine and alemtuzumab as conditioning for allogeneic hematopoietic stem cell transplant: reduced clearance at high doses and occurrence of late sinusoidal obstruction syndrome/veno-occlusive disease. ( Artz, AS; Del Cerro, P; Godley, LA; Hart, J; Horowitz, S; Innocenti, F; Larson, RA; O'Donnell, PH; Odenike, OM; Pai, RK; Stock, W; Undevia, SD; Van Besien, K, 2010)
"The final pharmacokinetic parameter were the clearance (CL/F) = 0."	2.75	Population pharmacokinetic study of a test dose oral busulfan in Japanese adult patients undergoing hematopoietic stem cell transplantation. ( Hara, S; Jimi, S; Ogata, K; Sasaki, N; Takamatsu, Y; Tamura, K; Yukawa, E, 2010)
" Pharmacokinetic (PK) data were compared with those previously collected in patients (n=127) treated with phenytoin for seizure prophylaxis."	2.75	Influence on Busilvex pharmacokinetics of clonazepam compared to previous phenytoin historical data. ( Bacigalupo, A; Buzyn, A; Cahn, JY; Carreras, E; Kröger, N; Puozzo, C; Sanz, G; Vernant, JP, 2010)
" In the (T)BU/CY patients only, the association of the pharmacokinetic data with liver toxicity, relapse, and survival was evaluated."	2.73	Cyclophosphamide following targeted oral busulfan as conditioning for hematopoietic cell transplantation: pharmacokinetics, liver toxicity, and mortality. ( Batchelder, A; Cole, S; Deeg, HJ; Gooley, T; McCune, JS; McDonald, GB; Phillips, B; Schoch, HG, 2007)
" The pharmacokinetic (PK) properties of F-ara-A (9-beta-D-arabinosyl-2-fluoradenine) before and after application of busulfan were prospectively investigated in 16 patients with hematological malignancies."	2.73	F-ara-A pharmacokinetics during reduced-intensity conditioning therapy with fludarabine and busulfan. ( Bergeman, T; Bonin, M; Bornhauser, M; Ehninger, G; Illmer, T; Leopold, T; Pursche, S; Schleyer, E, 2007)
"The incidence of toxicity excluding oral mucositis was low, and there was no regimen-related toxicity-associated mortality."	2.73	Individual dose adjustment of oral busulfan using a test dose in hematopoietic stem cell transplantation. ( Abe, Y; Choi, I; Eto, T; Hara, S; Nagafuji, K; Ogata, K; Sasaki, N; Suzumiya, J; Takamatsu, Y; Tamura, K, 2007)
"Older patients with advanced hematologic malignancies achieve satisfactory outcomes using either of these reduced intensity conditioning regimens."	2.73	Fludarabine vs cladribine plus busulfan and low-dose TBI as reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation: a prospective randomized trial. ( Arora, M; Barker, JN; Blazar, BR; Burns, LJ; DeFor, T; Douek, D; MacMillan, ML; Markova, M; Miller, JS; Repka, T; Tan, Y; Wagner, JE; Weisdorf, DJ, 2007)
" Dose-escalated treosulphan (3 x 12 or 3 x 14 g/m2) combined with cyclophosphamide (Cy) was chosen for a new preparative regimen before allogeneic haematopoietic stem cell transplantation in 18 patients (median age 44, range 19-64 years) with haematological malignancies, considered ineligible for other myeloablative preparative regimens."	2.71	Dose-escalated treosulphan in combination with cyclophosphamide as a new preparative regimen for allogeneic haematopoietic stem cell transplantation in patients with an increased risk for regimen-related complications. ( Basara, N; Baumgart, J; Beelen, DW; Casper, J; Fauser, AA; Freund, M; Hahn, JR; Hertenstein, B; Hilger, RA; Holler, E; Mylius, HA; Pichlmeier, U; Scheulen, ME; Trenschel, R, 2005)
" On the basis of the dosing guidelines and schedule outlined in this study, our data suggest that administration of IV Bu 3."	2.71	Dose modification protocol using intravenous busulfan (Busulfex) and cyclophosphamide followed by autologous or allogeneic peripheral blood stem cell transplantation in patients with hematologic malignancies. ( Abbott, BL; Abhyankar, S; Bechtel, T; Copelan, EA; Day, SD; Leather, HL; McGuirk, JP; Reed, MD; Williams, CB; Wingard, JR, 2004)
" Initial dosing of i."	2.71	I.V. busulfan in pediatrics: a novel dosing to improve safety/efficacy for hematopoietic progenitor cell transplantation recipients. ( Fuller, D; Leger, F; Lennon, S; Nguyen, L; Puozzo, C, 2004)
"Seizure is a recognized complication of high-dose busulfan (BU) therapy and phenytoin (DPH) is widely used as prophylaxis."	2.70	Lorazepam for seizure prophylaxis during high-dose busulfan administration. ( Chan, KW; Choroszy, M; Koontz, S; Mullen, CA; Slopis, J; Tran, H; Worth, LL, 2002)
" Pharmacokinetic studies were done using 11 samples with the first and fourth doses of Bu."	2.70	Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. ( Andersson, BS; Brown, C; Chaudhry, A; Duggan, P; Glick, S; Gyonyor, E; Morris, D; Quinlan, D; Ruether, JD; Russell, JA; Stewart, D; Tran, HT, 2002)
" A dosage schedule based on body surface area should be used especially in young children to reduce the age-dependent difference in kinetics."	2.70	A phase II trial of liposomal busulphan as an intravenous myeloablative agent prior to stem cell transplantation: 500 mg/m(2) as a optimal total dose for conditioning. ( Aschan, J; Eber, S; Gungor, T; Hassan, M; Hassan, Z; Hentschke, P; Ljungman, P; Nilsson, C; Ringdén, O; Seger, R; Winiarski, J, 2002)
" Bu was used as reference solution, the pharmacokinetic analysis indicated an average bioavailability of oral high-dose Bu of 69%, ranging from <10% to virtually 100%."	2.69	Acute safety and pharmacokinetics of intravenous busulfan when used with oral busulfan and cyclophosphamide as pretransplantation conditioning therapy: a phase I study. ( Andersson, BS; Blume, KG; Champlin, RE; Chow, DS; Hu, WW; Madden, T; Tran, HT; Vaughan, WP, 2000)
"We treated 51 patients with various hematological malignancies involving the bone marrow with busulfan (16 mg/kg) and cyclophosphamide (120 mg/kg) followed by reinfusion of autologous peripheral blood stem cells."	2.68	Phase I-II study of high-dose busulfan and cyclophosphamide followed by autologous peripheral blood stem cell transplantation for hematological malignancies: toxicities and hematopoietic recovery. ( Agaliotis, DP; Ballester, OF; Elfenbein, GJ; Fields, KK; Goldstein, SC; Hiemenz, JW; Janssen, WE; Perkins, JB; Zorksy, PE, 1996)
"Busulfan has been investigated widely for more than three decades leading to a large and precise handling of this agent with numerous studies on activity and pharmacokinetics and pharmacodynamics."	2.49	Pharmacology of dimethanesulfonate alkylating agents: busulfan and treosulfan. ( Galaup, A; Paci, A, 2013)
"Leukemic cells from many patients with acute myelogenous leukemia (AML) have surface receptors for CSFs and may proliferate in response to CSFs."	2.40	Cytokine therapy for hematological malignancies. ( Ezaki, K; Tsuzuki, M, 1997)
"In conclusion, ATG and PTCy combined with Flu-based increased intensity conditioning regimen is effective for acute leukemia in children."	1.91	Intensified conditioning regimen with fludarabine combined with post-transplantation cyclophosphamide for haploidentical allogeneic hematopoietic stem cell transplantation in children with high-risk acute leukemia. ( Cao, J; Chen, D; Li, S; Liu, X; Lu, Y; Pei, R; Wang, T; Xu, X; Ye, P; Zheng, ZZ, 2023)
"All patients had high-risk hematologic malignancies, were younger than 20 years, and were in complete cytological remission at the time of allo-HSCT."	1.91	Effective T-cell replete haploidentical stem cell transplantation for pediatric patients with high-risk hematologic disorders. ( Andersson, BS; Anurathapan, U; Hongeng, S; Pakakasama, S; Pongpitcha, P; Sirachainan, N; Songdej, D; Tannumsaeung, S, 2023)
" Studies on the interactions of HDACi with PARP inhibitors in hematologic cancers are limited, especially when combined with chemotherapeutic agents."	1.72	HDAC inhibitors suppress protein poly(ADP-ribosyl)ation and DNA repair protein levels and phosphorylation status in hematologic cancer cells: implications for their use in combination with PARP inhibitors and chemotherapeutic drugs. ( Andersson, BS; Murray, D; Nieto, Y; Valdez, BC; Yuan, B, 2022)
"Busulfan (Bu) is an alkylating agent routinely used for conditioning regimens before allogeneic stem cell transplantation (allo-SCT)."	1.62	Feasibility and Efficacy of a Pharmacokinetics-Guided Busulfan Conditioning Regimen for Allogeneic Stem Cell Transplantation with Post-Transplantation Cyclophosphamide as Graft-versus-Host Disease Prophylaxis in Adult Patients with Hematologic Malignancie ( Bartoli, A; Bramanti, S; Castagna, L; De Gregori, S; De Philippis, C; Giordano, L; Mannina, D; Mariotti, J; Pieri, G; Roperti, M; Sarina, B; Valli, V, 2021)
" In this study, we aimed to investigate the side effect of Bu/Cy and Bu/Flu regimens on our patients who underwent allogeneic bone marrow transplantation."	1.62	Adverse Effects of Busulfan Plus Cyclophosphamide versus Busulfan Plus Fludarabine as Conditioning Regimens for Allogeneic Bone Marrow Transplantation. ( Hajifathali, A; Mabani, M; Mehdizadeh, M; Parkhideh, S; Rezvani, H; Salari, S, 2021)
" From a large cohort of 540 patients, we developed a Bu population pharmacokinetic model based on body weight (BW) and maturation concepts to reduce IIV and optimize exposure."	1.56	New dosing nomogram and population pharmacokinetic model for young and very young children receiving busulfan for hematopoietic stem cell transplantation conditioning. ( Bondu, S; Bourget, P; Broutin, S; Dalle, JH; De Berranger, E; Devictor, B; Dufour, C; Faivre, L; Galambrun, C; Gandemer, V; Jubert, C; Kemmel, V; Mir, O; Moshous, D; Neven, B; Nguyen, L; Paci, A; Petain, A; Poinsignon, V; Vannier, JP; Vassal, G, 2020)
"Factors independently associated with delayed puberty were extensive chronic GVHD (P = ."	1.56	Pubertal outcomes of children transplanted with allogeneic stem cells after myeloablative total body irradiation or busulfan: Influence of age and sex is confirmed, while a role of chronic graft-versus-host disease in delayed puberty onset is revealed. ( Dalle, JH; Lebon Labich, B; Leheup, B; Pochon, C; Weinhard, S; Wiedemann, A, 2020)
"Busulfan (Bu) is an alkylating agent commonly used in preparative regimens for hematologic malignant and non-malignant patients undergoing hematopoietic stem cell transplantation (HSCT)."	1.56	UPLC-Tandem Mass Spectrometry for Quantification of Busulfan in Human Plasma: Application to Therapeutic Drug Monitoring. ( Alshemmari, SH; Anwar, A; Matar, KM; Refaat, S, 2020)
"Busulfan has a narrow therapeutic index and its concentration was found to correlate with VOD."	1.56	Busulfan clearance does not predict the development of hepatic veno-occlusive disease in patients undergoing hematopoietic stem cell transplantation. ( Al-Huneini, M; Al-Khabori, M; Al-Rawas, A; Al-Za'abi, M; Dennison, D; Salman, B, 2020)
"The most common primary cancer was acute lymphoblastic leukemia (22 patients, 31."	1.56	Factors predicting endocrine late effects in childhood cancer survivors from a Japanese hospital. ( Kazukawa, I; Kihara, M; Minagawa, M; Mori, K; Shimazaki, S, 2020)
"Alopecia was defined as clinically apparent decreased hair density."	1.46	Permanent diffuse alopecia after haematopoietic stem cell transplantation in childhood. ( Ball, LM; Bresters, D; Fiocco, M; Louwerens, M; van Doorn, R; Wanders, DCM, 2017)
"Busulfan was administered in four daily divided doses either orally (n = 72) or intravenously (n = 59) with pharmacokinetics on the first-dose and as necessary on subsequent doses to achieve a target area-under-the-concentration-curve (AUC) of 800-1400 μmol*min/L per dose."	1.43	Therapeutic drug monitoring for either oral or intravenous busulfan when combined with pre- and post-transplantation cyclophosphamide. ( Ambinder, RF; Bolaños-Meade, J; Borrello, I; Brodsky, RA; Durakovic, N; Fuchs, EJ; Gladstone, DE; Huff, CA; Jones, RJ; Kanakry, CG; Kasamon, YL; Lombardi, LR; Luznik, L; Matsui, W; Rosner, GL; Swinnen, LJ; Zahurak, M, 2016)
"However, the effect of Gilbert's syndrome on the disposition of some drugs can lead to unexpected toxicity."	1.43	Mortality outcomes after busulfan-containing conditioning treatment and haemopoietic cell transplantation in patients with Gilbert's syndrome: a retrospective cohort study. ( Evans, AT; Gooley, TA; McCune, JS; McDonald, GB; Ostrow, JD; Schoch, G, 2016)
"A total of 30 patients with hematologic malignancies (8 cases of AML, 17 AML, 2 MDS and 3 Mix-AL) received related haploidentical and unrelated HLA-mismatched allo-HSCT combined with related haploidentical bone marrow infusion."	1.43	[Two Kinds of HLA-mismatched Allogeneic Hematopoictic Stem Cell Transplantation for Treatment of Hematologic Malignancies]. ( Gao, ZY; Li, WD; Lu, DP; Lu, DY; Yu, XJ, 2016)
" We aimed this retrospective study for comparison of weight- and age-based dosing in terms of clinical outcomes such as time to engraftment, early complications, EFS, OS, and toxicity profiles in children receiving iv Bu."	1.42	Clinical comparison of weight- and age-based strategy of dose administration in children receiving intravenous busulfan for hematopoietic stem cell transplantation. ( Avci, Z; Azik, F; Gürlek Gökçebay, D; Isik, P; Kara, A; Ozbek, N; Tavil, B; Tunc, B, 2015)
"Oral mucositis was reduced in patients treated with RIC and in patients treated during recent years, when oral care was intensified."	1.40	Reduced intensity conditioning and oral care measures prevent oral mucositis and reduces days of hospitalization in allogeneic stem cell transplantation recipients. ( Dahllöf, G; Heimdahl, A; Legert, KG; Remberger, M; Ringdén, O, 2014)
" Our data indicate that Flu (160 mg/m(2)) with targeted myeloablative Bu (90 mg·h/L) is less toxic than and equally effective as BuCy (Mel) in patients with similar indications for allo-HCT."	1.40	Fludarabine and exposure-targeted busulfan compares favorably with busulfan/cyclophosphamide-based regimens in pediatric hematopoietic cell transplantation: maintaining efficacy with less toxicity. ( Bartelink, IH; Bierings, MB; Boelens, JJ; de Wildt, A; Gerhardt, CE; Lindemans, CA; van Maarseveen, EM; van Reij, EM; Versluys, B, 2014)
"Busulfan (Bu) is a DNA-alkylating agent used for myeloablative conditioning in stem cell transplantation in children and adults."	1.40	Evaluation of effects of busulfan and DMA on SOS in pediatric stem cell recipients. ( Bartelink, I; Boelens, J; Boos, J; Diestelhorst, C; Hempel, G; Kerl, K; Trame, MN, 2014)
"Modified Bu/Flu as a new RIC regimen is well tolerated and safe for patients who need allogeneic hematopoietic stem cell transplantation, especially in older patients and/or patients with severe comorbidities."	1.39	[The efficacy and safety of modified busulfan/fludarabine conditioning regimen in elderly or drug-intolerable patients with hematologic malignancies]. ( Chen, H; Fu, HX; Huang, XJ; Liu, DH; Liu, KY; Sun, YQ; Tang, FF; Wang, FR; Wang, Y; Xu, LP, 2013)
"A prospective clinical trial was performed in order to validate the pharmacokinetic (PK) and clinical benefits of a new dosing schedule of intravenous busulfan (IV Bu) in children."	1.38	Weight-based strategy of dose administration in children using intravenous busulfan: clinical and pharmacokinetic results. ( Bertrand, Y; Bordigoni, P; Demeocq, F; Doz, F; Esperou, H; Frappaz, D; Galambrun, C; Gentet, JC; Méchinaud, F; Michel, G; Neven, B; Nguyen, L; Socié, G; Valteau-Couanet, D; Vassal, G; Yakouben, K, 2012)
"The clinical advantage of pharmacokinetic (PK)-directed-based dosing on intravenous (i."	1.38	Pharmacokinetic-directed high-dose busulfan combined with cyclophosphamide and etoposide results in predictable drug levels and durable long-term survival in lymphoma patients undergoing autologous stem cell transplantation. ( Ali, Z; Dada, MO; Flowers, CR; Graiser, M; Hutcherson, DA; McMillan, S; Waller, EK; Zhang, H, 2012)
"Acute kidney injury was defined as doubling serum creatinine from baseline at any time during the first 180 days posttransplant."	1.36	Frequency, risk factors, and outcome of acute kidney injury following bone marrow transplantation at Dr Shariati Hospital in Tehran. ( Attari, F; Bahar, B; Falaknazi, K; Hakemi, MS; Najafi, I; Saddadi, F, 2010)
"A prevalence of sleep disorders of 26."	1.36	Association of busulfan and cyclophosphamide conditioning with sleep disorders after hematopoietic stem cell transplantation. ( Astigarraga, CC; Faulhaber, GA; Furlanetto, TW; Moser Filho, HL; Paludo, AP; Silla, LM, 2010)
"Hyperbilirubinemia was graded according to a report by Hogan et al (Blood."	1.33	Hepatic injury following reduced intensity unrelated cord blood transplantation for adult patients with hematological diseases. ( Fujiwara, M; Hori, A; Kami, M; Kanda, Y; Komatsu, T; Koyama, R; Kusumi, E; Masuoka, K; Matsumura, T; Miyakoshi, S; Murashige, N; Seki, K; Tanaka, Y; Taniguchi, S; Wake, A; Yuji, K, 2006)
"Cataracts affect a minority of long-term cancer survivors, but those who reported them were more likely to report that cancer had had a lasting effect on their overall health."	1.33	Cataracts among cancer survivors. ( Beck, M; Stava, C; Vassilopoulou-Sellin, R, 2005)
"In order to observe the curative and side effects in malignant hematologic diseases treated with autologous peripheral blood stem cell transplantation (auto-PBSCT) combined with halotype lymphocyte infusion, auto-PBSCs were mobilized, harvested and stored at -196 degrees C from patients in first CR or PR with intensive chemotherapy (Ara-C 1."	1.32	[Treatment of malignant hematologic diseases by peripheral blood stem cell transplantation combined with halotype lymphocyte infusion]. ( Guo, KY; Song, CY; Wu, BY; Wu, GX; Xiao, LL; Yan, DA; Yang, YL, 2003)
" Variability due to drug metabolism remains, but simplified pharmacokinetic study may be employed to achieve a specific target AUC."	1.31	A limited sampling strategy for pharmacokinetic directed therapy with intravenous busulfan. ( Carey, D; Perry, S; Salzman, DE; Vaughan, WP; Westfall, AO, 2002)
"Allantoin was analyzed as the product of uric acid oxidation."	1.31	Impaired plasma antioxidative defense and increased nontransferrin-bound iron during high-dose chemotherapy and radiochemotherapy preceding bone marrow transplantation. ( Berger, HM; Dürken, M; Finckh, B; Fischer, R; Herrnring, C; Kohlschütter, A; Kohlschütter, B; Moison, RM; Nagel, S; Nielsen, P; Pichlmeier, U; Zander, AR, 2000)
"Busulfan doses were decreased in 69% of patients compared to conventional doses."	1.31	Improved clinical outcome of paediatric bone marrow recipients using a test dose and Bayesian pharmacokinetic individualization of busulfan dosage regimens. ( Aulagner, G; Bertrand, Y; Bleyzac, N; Dai, Q; Galambrun, C; Janoly, A; Jelliffe, RW; Magron, P; Maire, P; Martin, P; Souillet, G, 2001)

Research

Studies (198)

Authors

Clinical Trials (22)

Trial Overview

Trial Outcomes

Non-Relapse Mortality Rate (NRM)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	8 (4.04)	18.2507
2000's	77 (38.89)	29.6817
2010's	92 (46.46)	24.3611
2020's	21 (10.61)	2.80

Authors	Studies
Jurkovic Mlakar, S	1
Uppugunduri, SCR	1
Nava, T	1
Mlakar, V	1
Golay, H	1
Robin, S	1
Waespe, N	1
Rezgui, MA	1
Chalandon, Y	2
Boelens, JJ	2
Bredius, RGM	1
Dalle, JH	3
Peters, C	2
Corbacioglu, S	1
Bittencourt, H	1
Krajinovic, M	1
Ansari, M	2
Ali, N	1
Sharma, AA	1
de Rezende, ACP	1
Otegbeye, F	1
Latif, BM	1
Kerbauy, MN	1
Cooper, BW	1
Sanchez, G	1
Metheny, L	1
Bal, SK	1
Sakuraba, R	1
Tomlinson, BK	1
Boughan, KM	1
Kerbauy, L	1
Malek, E	1
Ribeiro, AF	1
Gallogly, M	1
Mansur, D	1
Pereira, G	1
Weltman, E	1
Sekaly, RP	1
de Lima, M	3
Caimi, PF	1
Hamerschlak, N	1
Valdez, BC	3
Nieto, Y	3
Yuan, B	1
Murray, D	1
Andersson, BS	12
Tannumsaeung, S	3
Anurathapan, U	3
Pakakasama, S	3
Pongpitcha, P	3
Songdej, D	3
Sirachainan, N	3
Hongeng, S	3
Malkan, ÜY	1
Göker, H	1
Demiroğlu, H	1
Tekin, F	1
Akdemir, NB	1
Karakulak, EA	1
Sayınalp, N	1
Haznedaroğlu, İC	1
Özcebe, Oİ	1
Büyükaşık, Y	1
Iemura, T	1
Kondo, T	2
Ueda, A	1
Maeda, T	2
Kitawaki, T	1
Arai, Y	1
Kanda, J	2
Ikeda, T	2
Imada, K	1
Ishikawa, T	2
Anzai, N	1
Itoh, M	1
Takeoka, T	1
Akasaka, T	1
Yago, K	1
Yonezawa, A	1
Arima, N	1
Kitano, T	1
Nohgawa, M	1
Watanabe, M	1
Moriguchi, T	1
Yamashita, K	1
Ueda, Y	2
Matsumoto, K	2
Takaori-Kondo, A	1
Cao, J	1
Xu, X	1
Lu, Y	1
Wang, T	2
Chen, D	1
Li, S	2
Liu, X	2
Ye, P	1
Zheng, ZZ	1
Pei, R	1
Terakura, S	2
Onizuka, M	1
Fukumoto, M	1
Kuwatsuka, Y	1
Kohno, A	1
Ozawa, Y	2
Miyamura, K	1
Inagaki, Y	1
Sawa, M	1
Atsuta, Y	4
Suzuki, R	3
Naoe, T	1
Morishita, Y	1
Murata, M	1
Shimazaki, S	1
Kazukawa, I	1
Mori, K	1
Kihara, M	1
Minagawa, M	1
Esquirol, A	1
Querol, S	1
Garcia-Cadenas, I	1
Novelli, S	1
Garrido, A	1
Saavedra, S	1
Moreno, C	1
Granell, M	2
Caballero, A	1
Brunet, S	1
Briones, J	1
Martino, R	2
Sierra, J	2
Huttunen, P	1
Taskinen, M	1
Vettenranta, K	1
Salman, B	1
Al-Khabori, M	1
Al-Huneini, M	1
Al-Rawas, A	1
Dennison, D	1
Al-Za'abi, M	1
Matar, KM	1
Alshemmari, SH	1
Refaat, S	1
Anwar, A	1
Weinhard, S	1
Wiedemann, A	1
Leheup, B	1
Lebon Labich, B	1
Pochon, C	1
Poinsignon, V	1
Faivre, L	1
Nguyen, L	3
Neven, B	2
Broutin, S	1
Moshous, D	1
Bourget, P	1
Dufour, C	1
Galambrun, C	3
Devictor, B	1
Kemmel, V	1
De Berranger, E	1
Gandemer, V	1
Vannier, JP	1
Jubert, C	1
Bondu, S	1
Mir, O	1
Petain, A	1
Vassal, G	2
Paci, A	2
Seydoux, C	1
Medinger, M	1
Gerull, S	1
Halter, J	1
Heim, D	1
Levrat, SM	1
Schanz, U	1
Nair, G	1
Simon, P	1
Passweg, JR	1
Cantoni, N	1
Edahiro, T	1
Kawase, T	1
Nagoshi, H	1
Fujino, K	1
Toishigawa, K	1
Miyama, T	1
Mino, T	1
Yoshida, T	2
Morioka, T	1
Hirata, Y	1
Noma, M	1
Fujii, T	1
Nishizawa, M	1
Fukushima, N	1
Ichinohe, T	4
Shimomura, Y	1
Hara, M	2
Yamamoto, H	1
Uchida, N	2
Kawakita, T	2
Ashida, T	1
Takada, S	1
Morishige, S	1
Maruyama, Y	1
Wake, A	2
Fukuda, T	5
Takanashi, M	1
Konuma, T	1
Monna-Oiwa, M	1
Isobe, M	1
Okabe, M	1
Takahashi, S	1
Tojo, A	1
Mehdizadeh, M	1
Parkhideh, S	1
Salari, S	1
Hajifathali, A	1
Rezvani, H	1
Mabani, M	1
Bramanti, S	1
De Philippis, C	1
Bartoli, A	1
Giordano, L	1
Mariotti, J	1
Sarina, B	1
Mannina, D	1
Valli, V	1
De Gregori, S	1
Roperti, M	1
Pieri, G	1
Castagna, L	6
Bresters, D	2
Wanders, DCM	1
Louwerens, M	1
Ball, LM	1
Fiocco, M	1
van Doorn, R	1
Gooptu, M	1
Kim, HT	4
Ho, VT	3
Alyea, EP	4
Koreth, J	3
Armand, P	3
Ritz, J	3
Nikiforow, S	2
Glotzbecker, BE	1
Nageshwar, P	1
Soiffer, RJ	4
Antin, JH	4
Cutler, CS	2
Kako, S	1
Fujiwara, S	1
Sato, M	1
Kimura, SI	1
Nakasone, H	1
Ohashi, K	2
Morishita, T	1
Kurata, M	1
Kanda, Y	8
Sweiss, K	3
Oh, A	2
Calip, G	1
Rondelli, D	4
Patel, P	2
Popat, UR	1
Mehta, RS	1
Bassett, R	2
Chen, J	2
Kawedia, J	1
Ahmed, S	2
Alousi, AM	2
Anderlini, P	2
Al-Atrash, G	1
Bashir, Q	1
Ciurea, SO	1
Hosing, CM	1
Im, JS	1
Jones, R	3
Kebriaei, P	3
Khouri, I	3
Marin, D	1
Olson, A	1
Oran, B	2
Parmar, S	2
Rezvani, K	1
Qazilbash, MH	1
Shah, N	2
Srour, SA	1
Shpall, EJ	2
Champlin, RE	5
Calip, GS	1
Oh, AL	1
Patel, PR	1
Duléry, R	1
Bastos, J	1
Paviglianiti, A	1
Malard, F	3
Brissot, E	1
Battipaglia, G	1
Médiavilla, C	1
Giannotti, F	1
Banet, A	1
de Wyngaert, ZV	1
Ledraa, T	1
Belhocine, R	1
Sestili, S	1
Adaeva, R	1
Lapusan, S	1
Isnard, F	1
Legrand, O	1
Vekhoff, A	1
Rubio, MT	1
Ruggeri, A	1
Mohty, M	7
McCune, JS	6
Bo-Subait, K	1
Aljurf, M	1
Beitinjaneh, A	1
Bubalo, J	1
Cahn, JY	3
Cerny, J	1
Chhabra, S	1
Cumpston, A	2
Dupuis, LL	1
Lazarus, HM	1
Marks, DI	3
Maziarz, RT	3
Norkin, M	1
Prestidge, T	1
Mineishi, S	5
Krem, MM	1
Pasquini, M	1
Martin, PJ	3
Saco, A	1
Alòs, S	1
Esteve, R	1
Suárez-Lledó, M	1
Martínez, C	2
Perez, FM	1
Vega, N	1
Martí, C	1
Torne, A	1
Ordi, J	1
Del Pino, M	1
Le Bourgeois, A	1
Mohr, C	1
Guillaume, T	2
Delaunay, J	2
Loirat, M	1
Peterlin, P	1
Blin, N	1
Dubruille, V	1
Mahe, B	1
Gastinne, T	1
Le Gouill, S	2
Moreau, P	2
Planche, L	1
Lode, L	1
Bene, MC	1
Chevallier, P	2
Kharfan-Dabaja, MA	2
Anasetti, C	2
Fernandez, HF	4
Perkins, J	1
Ochoa-Bayona, JL	1
Pidala, J	1
Perez, LE	2
Ayala, E	2
Field, T	1
Alsina, M	1
Nishihori, T	1
Locke, F	1
Pinilla-Ibarz, J	1
Tomblyn, M	1
Kumar, AJ	1
Hexner, EO	1
Frey, NV	1
Luger, SM	1
Loren, AW	1
Reshef, R	1
Boyer, J	1
Smith, J	1
Stadtmauer, EA	1
Levine, BL	1
June, CH	1
Porter, DL	1
Goldstein, SC	2
Saillard, C	1
Crocchiolo, R	3
Furst, S	6
El-Cheikh, J	4
Signori, A	1
Oudin, C	2
Faucher, C	5
Lemarie, C	4
Chabannon, C	6
Granata, A	3
Blaise, D	10
Russell, JA	8
Kangarloo, SB	3
Williamson, T	2
Chaudhry, MA	6
Savoie, ML	5
Turner, AR	4
Larratt, L	4
Storek, J	6
Bahlis, NJ	6
Shafey, M	2
Brown, CB	4
Yang, M	3
Geddes, M	6
Zacarias, N	4
Yue, P	2
Duggan, P	5
Stewart, DA	5
Daly, A	5
Yu, ZP	1
Ding, JH	1
Chen, BA	1
Li, YF	1
Ding, BH	1
Qian, J	1
Devillier, R	2
Harbi, S	2
D'Incan, E	1
Coso, D	2
Picard, C	1
Etienne, A	1
Calmels, B	3
Schiano, JM	1
Stoppa, AM	5
Bouabdallah, R	4
Vey, N	5
Kerl, K	1
Diestelhorst, C	1
Bartelink, I	1
Boelens, J	1
Trame, MN	1
Boos, J	1
Hempel, G	1
Bartelink, IH	1
van Reij, EM	1
Gerhardt, CE	1
van Maarseveen, EM	1
de Wildt, A	1
Versluys, B	1
Lindemans, CA	1
Bierings, MB	1
Mohty, B	1
Charbonnier, A	1
Broussais-Guillaumot, F	1
Rey, J	1
Yeh, SP	1
Lo, WC	1
Hsieh, CY	1
Bai, LY	1
Lin, CC	1
Lin, PH	1
Lin, CY	1
Liao, YM	1
Chiu, CF	1
Rauenzahn, S	1
Truong, Q	1
Goff, L	1
Leadmon, S	1
Evans, K	1
Zhang, J	1
Wen, S	1
Craig, M	1
Hamadani, M	2
Kanate, AS	1
Wang, FR	2
Huang, XJ	2
Liu, DH	3
Chen, H	2
Wang, Y	2
Tang, FF	1
Sun, YQ	2
Fu, HX	1
Liu, KY	2
Xu, LP	2
Okamoto, Y	1
Nagatoshi, Y	2
Kosaka, Y	1
Kikuchi, A	1
Kato, S	1
Kigasawa, H	1
Horikoshi, Y	1
Oda, M	1
Kaneda, M	1
Mori, T	1
Mugishima, H	1
Tsuchida, M	1
Taniguchi, S	5
Kawano, Y	4
Choi, I	2
Yoon, SR	1
Park, SY	1
Kim, H	1
Jung, SJ	1
Jang, YJ	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
Polymorphisms and Busulfan Pharmacokinetic Study in Pediatric Transplnatation[NCT01257854]		200 participants (Anticipated)	Observational	2008-02-29	Recruiting
A Clinical Study of Low-dose Total Body Irradiation and Fludarabine/Busulfan/Melphalan as a Conditioning Regimen for Secondary Umbilical Cord Blood Transplantation in Patients With Hematological Malignancies Who Relapsed After Allo-HSCT[NCT06125483]		38 participants (Anticipated)	Interventional	2023-11-01	Recruiting
Phase II Study of Timed Sequential Busulfan in Combination With Fludarabine in Allogeneic Stem Cell Transplantation[NCT01572662]	Phase 2	201 participants (Actual)	Interventional	2012-04-11	Completed
Phase I Trial of Haploidentical Natural Killer (NK) Cells in Combination With Pemetrexed in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)[NCT03366064]	Phase 1	5 participants (Actual)	Interventional	2017-11-09	Completed
Cryoprotection of Chemotherapy-induced Oral Mucositis After Autologous Stem Cell Transplantation, a Randomized Study[NCT03203733]		182 participants (Actual)	Interventional	2017-06-12	Completed
A Phase I Study of Intensity Modulated Total Marrow Irradiation (IM-TMI) in Addition to Fludarabine/Busulfan Conditioning for Allogeneic Transplantation for Advanced Hematologic Malignancies[NCT00988013]		14 participants (Actual)	Interventional	2009-09-30	Completed
A Randomized,Open,Multicenter and Prospective Study of the Optimized Dose of Anti-Thymoglobuline in Haploidentical Allogeneic Stem Cell Transplantation[NCT03190733]	Phase 4	192 participants (Anticipated)	Interventional	2017-08-30	Not yet recruiting
Bortezomib-based Graft-Versus-Host-Disease Prophylaxis After Myeloablative Allogeneic Stem Cell Transplantation for Patients Lacking HLA-matched Related Donors: A Phase 2 Study[NCT01323920]	Phase 2	35 participants (Actual)	Interventional	2011-05-31	Completed
Allogeneic Hematopoietic Cell Transplantation for Patients With Hematologic Disorders Who Are Undergoing Dose-Adjusted Treatment With A Maximally Intensive Busulfex-Based Therapeutic Regimen[NCT00448357]	Phase 1/Phase 2	54 participants (Actual)	Interventional	2005-10-31	Completed
A Randomized Study of a New Medical Device for Oral Mucositis (MDOM Trial)[NCT05104268]	Phase 1/Phase 2	100 participants (Anticipated)	Interventional	2021-11-30	Not yet recruiting
Low Power Laser Therapy As Prevention Of Oral Mucositis And Oropharyngeal Pain In Patients Undergoing Allogenetic Hematopoietic Stem Cell Transplantation.[NCT06071637]	Phase 3	84 participants (Anticipated)	Interventional	2023-08-01	Recruiting
A Phase II Study to Evaluate the Efficacy of Posttransplant Cyclophosphamide for Prevention of Chronic Graft-versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation[NCT01427881]	Phase 2	43 participants (Actual)	Interventional	2011-09-30	Completed
PRO#1278: A Phase III Study of Fludarabine and Busulfan Versus Fludarabine, Busulfan and Low Dose Total Body Irradiation in Patients Receiving an Allogeneic Hematopoietic Stem Cell Transplant[NCT01366612]	Phase 3	53 participants (Actual)	Interventional	2010-06-16	Terminated (stopped due to Lack of Accrual)
Prospective Study of Combined ATG Regimen for Prophylaxis of aGVHD in Matched Sibling Donor PBSCT[NCT02677181]	Phase 4	100 participants (Actual)	Interventional	2016-01-31	Completed
A Phase I-II Study of Busulfan-fludarabine Conditioning and T-cell Depleted Allogeneic Stem Cell Transplantation for Patients With Advanced Hematologic Malignancies[NCT00943319]	Phase 1/Phase 2	50 participants (Actual)	Interventional	2012-03-31	Completed
Impact of the Use of Zinc in the Prevention of Oral Mucositis in Pediatric Patients With Lymphoblastic Acute Leukemia.[NCT04321850]		21 participants (Actual)	Interventional	2019-06-10	Terminated (stopped due to Health restrictions due to the COVID-19 pandemic)
Busulfan Dose Escalation Study Based on AUC in the Setting of Busulfan/Fludarabine Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation (HCT)[NCT00361140]	Phase 4	72 participants (Actual)	Interventional	2005-08-31	Completed
Prospective Multicenter Phase II Study of Myeloablative Double Unit Umbilical Cord Blood Transplantation in Adult Patients With Hematologic Malignancies[NCT02385955]	Phase 2	39 participants (Anticipated)	Interventional	2015-04-30	Not yet recruiting
Bone Marrow Transplantation HLA Haploidentical After a Reduced Intensity Conditioning and Prevention of GvHD Based on Post-transplant Cyclophosphamide Administration in Patients With Severe Sickle Cell Disease[NCT03240731]	Phase 2	18 participants (Anticipated)	Interventional	2017-08-10	Active, not recruiting
Phase I/II Trial of Donor Derived Cytokine Induced Killer (CIK) Cells Infusion for Relapsed Hematologic Malignancy After Haploidentical Stem Cell Transplantation[NCT03821519]	Phase 1/Phase 2	20 participants (Anticipated)	Interventional	2019-01-13	Recruiting
Haploidentical Allogeneic Peripheral Blood Transplantation: Clinical Trial and Laboratory Correlates Examining Checkpoint Immune Regulators' Expression[NCT03480360]	Phase 3	20 participants (Anticipated)	Interventional	2018-03-28	Active, not recruiting
Allogeneic Stem Cell Transplantation Following Nonmyeloablative Chemotherapy in Patients With Hemoglobinopathies[NCT00034528]	Phase 2	2 participants (Actual)	Interventional	2001-09-30	Terminated (stopped due to Due to slow recruitment)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Number of participants expired within the first 100 days after transplant not due to relapsed disease. (NCT01572662)
Timeframe: 100 days

Overall Survival

Intervention	Participants (Count of Participants)
Arm 1: Participants w/Hematologic Malignancies Treated w/Fludarabine/TS Busulfan AUC 16,000 Umol/l	2
Arm 2: Participants w/Hematologic Malignancies Treated w/Fludarabine/TS Busulfan AUC 20,000umol/l.	8

Number of participants that are disease free and alive one year post transplant. (NCT01572662)
Timeframe: Up to 1 year post-transplant

Overall Survival

Intervention	Participants (Count of Participants)
Arm 1: Participants w/Hematologic Malignancies Treated w/Fludarabine/TS Busulfan AUC 16,000 Umol/l	29
Arm 2: Participants w/Hematologic Malignancies Treated w/Fludarabine/TS Busulfan AUC 20,000umol/l.	93

Number of participants that were diseased free and alive 3 years post-transplant. (NCT01572662)
Timeframe: Up to 3 years post-transplant

Number of Participants With 1 Year Mortality Unrelated to TMI

Number of Participants With Grade 4 TMI Toxicity

Time to Neutrophil and Platelet Engraftment in Patients With Hematologic Malignancies

The Cumulative Incidence of Chronic GVHD Requiring Systemic Immune Suppression up to 1 Year After Stem Cell Infusion

The Cumulative Incidence of Grade II-IV Acute GVHD up to Day 100 After Stem Cell Infusion

Intervention	Participants (Count of Participants)
Arm 1: Participants w/Hematologic Malignancies Treated w/Fludarabine/TS Busulfan AUC 16,000 Umol/l	16
Arm 2: Participants w/Hematologic Malignancies Treated w/Fludarabine/TS Busulfan AUC 20,000umol/l.	47

Intervention	Participants (Count of Participants)
IM-TMI (3Gy)	0
IM-TMI (6Gy)	0
IM-TMI (9Gy)	2
IM-TMI (12Gy)	2

Intervention	Participants (Count of Participants)
IM-TMI (3Gy)	0
IM-TMI (6Gy)	0
IM-TMI (12Gy)	0
IM-TMI (9Gy)	2

Intervention	Days (Median)
IM-TMI (3Gy)	15
IM-TMI (6Gy)	15
IM-TMI (9Gy)	15
IM-TMI (12Gy)	15

Intervention	Percentage of participants (Number)
Velcade/Tac/MTX	53

The primary outcome of this study is the cumulative incidence of grade II-IV acute GVHD up to Day 100 after stem cell infusion. Acute GHVD is graded according to the modified Glucksberg criteria (adapted from Thomas et al., NEJM ,1975, pp. 895-90), which is based on criteria by which the provider classifies acute GVHD per its objective organ staging. Acute GVHD is assessed in weekly standard of care visits post stem cell infusion and is captured in the protocol EDC upon evaluation of clinical notes up to Day 100. Data for acute GVHD organ staging and etiologies are collected in an acute GVHD separate case report form and do not include system organ class, expectedness or attribution. (NCT01323920)
Timeframe: Day 100

The Percentage Donor Engraftment up to Day 30 Post Stem Cell Infusion

Intervention	Percentage of participants (Number)
Velcade/Tac/MTX	32

To assess the percentage donor engraftment up to day 30 post stem cell infusion, defined as the first of 3 consecutive days tested of documented absolute netrophil count (ANC) >/= 500 cells/u/L (NCT01323920)
Timeframe: Day 30

The Non-relapse Mortality, Progression-free and Overall Survival up to 1 Year After Stem Cell Infusion

Intervention	Percentage of participants (Number)
Velcade/Tac/MTX	94

Progression free and overall survival by 1 year after stem cell infusion will be assessed using the method of Kaplan and Meier. Progression-free survival will be defined as the time from stem cell infusion to the time of disease progression or death from any cause. Overall survival will be defined as the time from stem cell infusion to the time to death from any cause. Patients will be censored at the time last documented alive. Cumulative incidence and Kaplan-Meier curves will be constructed as appropriate. Progression is defined per clinical presentation, not protocol specified, and vary per disease, e.g. blasts in bone marrow or peripheral blood for AML/MDS; lymphoma + on PET/CT re-staging etc. (NCT01323920)
Timeframe: 1 year

Capacity of Test Dosing of Busulfan That Would Result in the Desired Area Under the Curve Concentration Exposure of Patients Receiving a Full-dose Busulfan Regimen

Intervention	Percent of participants (Number)
	non-relapse mortality	progression-free survival	overall survival
Velcade/Tac/MTX	8.8	85	84

Test doses of busulfan were administered and plasma levels were measured to determine a targeted AUC dosing estimate. The capacity is reported as the precision with which these test dose goals predicted the actual 90-hour mean AUC levels.Dose targeting precision was estimated by root mean squared error. (NCT00448357)
Timeframe: Day -15 to Day -11

Number of Participants With Dose Limiting Toxicities (DLTs)

Intervention	percentage of error (Number)
Dose Level 1	11.7
Dose Level 2	4.9
Dose Level 3	10.2
Dose Level 4	11.1
Dose Level 5	15.9

Dose limiting toxicity will be defined as any irreversible grade 3 or any grade 4 non-hematologic toxicity that is related to busulfan infusion and not graft vs host disease or late infection after recovery from the initial period of myelosuppression. The maximum tolerated dose (MTD) is defined as the dose with probability of dose limiting toxicity (DLT) of 0.25. The dose of continuous infusion IV busulfan based on blood levels derived from a test dose in conjunction with fludarabine and alemtuzumab plus tacrolimus for GVHD prophylaxis. (NCT00448357)
Timeframe: first 6 weeks or 42 days following stem cell infusion

Overall Survival

Intervention	DLTs (Number)
Dose Level 1	1
Dose Level 2	1
Dose Level 3	1
Dose Level 4	2
Dose Level 5	2

Percentage of participants alive at 3 years post transplant (NCT00448357)
Timeframe: Three years post-transplant

Three-year Relapse-free Survival (RFS) Rate at the Maximum Tolerated Dose Identified During Phase I of the Trial (Target AUC 6912)

Intervention	percentage of participants (Number)
Low Busulfan AUC Tertile (5078)	28
Intermediate Busulfan AUC Tertile (6372)	39
High Busulfan AUC Tertile (7605)	55

Relapse is defined as new or increased sites of disease or positive one marrow after a complete response (CR). The RFS was calculated as the percentage of patients who were alive and without relapse at 3 years (NCT00448357)
Timeframe: Three years post-transplant

Incidence of DNA Chimerism in Patients Between One Month Post Transplant

Intervention	percentage of participants (Number)
Low Busulfan AUC Tertile	22
Intermediate Busulfan AUC Tertile	39
High Busulfan AUC Tertile	43

Deoxyribonucleic acid (DNA) chimerism is a measure identifying the genetic profiles of the transplant recipient and of the donor and then evaluating the extent of mixture in the recipient's blood, bone marrow, or other tissue. (NCT00448357)
Timeframe: 30 days post transplant

Incidence of Graft vs Host Disease in Patients Between One Month and Two Years Post Transplant

Intervention	Participants (Count of Participants)
	Whole blood chimerism-Any	Whole blood chimerism->=95% donor	T Cell chimerism-Any	T Cell chimerism>=95% donor
Experimental: GVHD Prophylaxis	49	47	46	30

"GVHD can be mild, moderate or severe depending on the differences in tissue type between patient and donor. GVHD can be acute or chronic. Its symptoms can include:~Rashes, which include burning and redness, that erupt on the palms or soles and may spread to the trunk and eventually to the entire body~Blistering, causing the exposed skin surface to flake off in severe cases~Nausea, vomiting, abdominal cramps, diarrhea and loss of appetite, which can indicate that the gastrointestinal (digestive) tract is affected~Jaundice, or a yellowing of the skin, which can indicate liver damage~Excessive dryness of the mouth and throat, leading to ulcers~Dryness of the lungs, vagina and other surfaces" (NCT00448357)
Timeframe: 100 days post transplant

Chronic GVHD Requiring Systemic Immunosuppressive Treatment

Intervention	Participants (Count of Participants)
	Acute GVHD grade >=II	Acute GVHD grades III and IV	Chronic GVHD; intermediate/severe
High Busulfan AUC Tertile	11	3	2
Intermediate Busulfan AUC Tertile	10	4	6
Low Busulfan AUC Tertile	7	2	4

Chronic GVHD will be defined by National Institutes of Health (NIH) criteria and requiring systemic treatment. A reduction in the cumulative incidence of GVHD from ~35% to ~15% at 1 year would represent a reasonable goal. A sample size of 42 patients provides 90% power to observe such a difference with one-side 5% type-1 error. (NCT01427881)
Timeframe: At 1 year after transplantation

Disease-free Survival

Intervention	percent of patients (Number)
Treatment (TBI, PBSCT, and Cyclophosphamide GVHD Prophylaxis)	16

Disease-free survival will be evaluated as Kaplan-Meier estimates. (NCT01427881)
Timeframe: At 1 year post-transplant

Donor Engraftment

Intervention	percentage of patients (Number)
Treatment (TBI, PBSCT, and Cyclophosphamide GVHD Prophylaxis)	73.8

Donor engraftment is defined as the count (percent) of patients with full donor chimerism. Full donor chimerism is defined as at least 95% donor CD3 cells in peripheral blood. (NCT01427881)
Timeframe: At day 28

Graft Failure

Intervention	Participants (Count of Participants)
Treatment (TBI, PBSCT, and Cyclophosphamide GVHD Prophylaxis)	6

Descriptive statistics will be used to assess the incidence of primary graft failure and secondary graft failure. Primary graft failure is defined as failure to achieve a sustained neutrophil count of >= 500/uL by >= 28 days post-transplant. Secondary graft failure is defined as the decline in neutrophil count to < 500/uL after achieving engraftment which is unrelated to infection or drug effect and is unresponsive to stimulation by growth factors. (NCT01427881)
Timeframe: By greater than or equal to 28 days post-transplant

Non-relapse Mortality

Intervention	percentage of patients (Number)
Treatment (TBI, PBSCT, and Cyclophosphamide GVHD Prophylaxis)	2

Defined as death in the absence of recurrent or progressive malignancy after HCT. Non-relapse morality will be assessed with the use of cumulative incidence plots. This secondary endpoint will be characterized and presented as a cumulative incidence. (NCT01427881)
Timeframe: At 2 years

Overall Survival

Intervention	percentage of patients (Number)
Treatment (TBI, PBSCT, and Cyclophosphamide GVHD Prophylaxis)	14

Overall survival will be evaluated as Kaplan-Meier estimates. (NCT01427881)
Timeframe: At 1 year post-transplant

Persistent or Recurrent Malignancy After HCT

Intervention	percentage of patients (Number)
Treatment (TBI, PBSCT, and Cyclophosphamide GVHD Prophylaxis)	75.6

Recurrent or progressive malignancy will be assessed with the use of cumulative incidence plots. Recurrent malignancy will be defined by hematologic criteria. Recurrent malignancy will also be defined as any unplanned medical intervention designed to prevent progression of malignant disease in patients who have molecular, cytogenetic or flow-cytometric evidence of malignant cells after transplantation. (NCT01427881)
Timeframe: At 2 years

Grades II-IV and III-IV Acute GVHD

Intervention	percentage of patients (Number)
Treatment (TBI, PBSCT, and Cyclophosphamide GVHD Prophylaxis)	17

Grades II-IV and III-IV GVHD will be assessed with the use of cumulative incidence plots. (NCT01427881)
Timeframe: Through day +100 post-transplant

Hematologic Recovery

Intervention	percentage of patients (Number)
	Grades II-IV GVHD	Grades III-IV GVHD
Treatment (TBI, PBSCT, and Cyclophosphamide GVHD Prophylaxis)	77	0

Descriptive statistics will be used to assess the median days of neutrophil and platelet recovery. The day of neutrophil recovery is defined as the first day of three consecutive lab values on different days, after the conditioning regimen-induced nadir of blood counts, that the absolute neutrophil count is > 500/uL. The day of platelet recovery is defined as the first day of three consecutive lab values on different days, after the conditioning regimen-induced nadir of blood counts, that the platelet count is >= 20,000/uL without platelet transfusion support in the seven days prior. (NCT01427881)
Timeframe: Up to day +100

To Compare the Relapse Rate at 1 Year of Patients With Myeloid Malignancies Receiving Each Treatment

Disease Free Survival

Intervention	days (Median)
	Neutrophil Engraftment	Platelet Engraftment
Treatment (TBI, PBSCT, and Cyclophosphamide GVHD Prophylaxis)	19	14

Intervention	Percent (Number)
Group 1	38.9
Group 2	18.8

Disease Free Survival measured by median survival time in days (NCT00943319)
Timeframe: 5 years

Maximum Tolerated Dose

Intervention	days (Median)
Busulfan and Fludarabine	172

Maximally tolerated area under the curve of intravenous busulfan (Busulfan®) in combination with fludarabine as conditioning regimen for transplantation with in-vivo T-cell depletion. The number reported will be an Area Under the Curve (AUC) measure reported in µmol-min/L. (NCT00943319)
Timeframe: 5 years

Overall Survival

Intervention	mmol-min/L (Number)
Busulfan and Fludarabine	6800

Overall Survival measured as median survival in days (NCT00943319)
Timeframe: 5 years

Non-relapse Mortality

Intervention	days (Median)
Busulfan and Fludarabine	161

The number of participants dead due to causes unrelated to relapse within the first 100 days post transplant. (NCT00361140)
Timeframe: 100 days

Severe Venous Occlusive Disease (VOD)/ Sinusoidal Obstructive Syndrome (SOS)

Intervention	participants (Number)
AUC 6000	3
AUC 7500	4
AUC 9000	2

The number of subjects with severe VOD / SOS; severity staged according to criteria set forth by McDonald G.B., Hinds M.S., Fisher L.D., et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. Ann Intern Med. 1993;118:255-267. Assessed within the first 100 days post transplant. (NCT00361140)
Timeframe: 100 days

Article	Year
The Incidence and Severity of Oral Mucositis among Allogeneic Hematopoietic Stem Cell Transplantation Patients: A Systematic Review. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2016, Volume: 22, Issue:4 Topics: Busulfan; Cyclophosphamide; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Tr	2016
The Incidence and Severity of Oral Mucositis among Allogeneic Hematopoietic Stem Cell Transplantation Patients: A Systematic Review. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2016, Volume: 22, Issue:4 Topics: Busulfan; Cyclophosphamide; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Tr	2016
The Incidence and Severity of Oral Mucositis among Allogeneic Hematopoietic Stem Cell Transplantation Patients: A Systematic Review. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2016, Volume: 22, Issue:4 Topics: Busulfan; Cyclophosphamide; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Tr	2016
The Incidence and Severity of Oral Mucositis among Allogeneic Hematopoietic Stem Cell Transplantation Patients: A Systematic Review. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2016, Volume: 22, Issue:4 Topics: Busulfan; Cyclophosphamide; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Tr	2016
Pharmacokinetics of high-dose i.v. treosulfan in children undergoing treosulfan-based preparative regimen for allogeneic haematopoietic SCT. Bone marrow transplantation, 2008, Volume: 42 Suppl 2 Topics: Adolescent; Antineoplastic Agents, Alkylating; Busulfan; Child; Child, Preschool; Dose-Response Rela	2008
Interstrand crosslink inducing agents in pretransplant conditioning therapy for hematologic malignancies. Environmental and molecular mutagenesis, 2010, Volume: 51, Issue:6 Topics: Adenine Nucleotides; Antineoplastic Agents; Arabinonucleosides; Busulfan; Clofarabine; Cross-Linking	2010
Pharmacology of dimethanesulfonate alkylating agents: busulfan and treosulfan. Expert opinion on drug metabolism & toxicology, 2013, Volume: 9, Issue:3 Topics: Administration, Oral; Animals; Antineoplastic Agents, Alkylating; Busulfan; Cyclophosphamide; Dose-R	2013
Do different conditioning regimens really make a difference? Hematology. American Society of Hematology. Education Program, 2012, Volume: 2012 Topics: Adult; Aged; Bone Marrow Transplantation; Busulfan; Graft vs Host Disease; Hematologic Neoplasms; Hu	2012
[Mini-transplantation from HLA-mismatched donors]. Nihon rinsho. Japanese journal of clinical medicine, 2003, Volume: 61, Issue:9 Topics: Animals; Antilymphocyte Serum; Bone Marrow Transplantation; Busulfan; Graft vs Host Disease; Hematol	2003
Male predominance among Japanese adult patients with late-onset hemorrhagic cystitis after hematopoietic stem cell transplantation. Bone marrow transplantation, 2003, Volume: 32, Issue:12 Topics: Adenoviridae Infections; Adenoviruses, Human; Adolescent; Adult; Aged; Anemia, Aplastic; BK Virus; B	2003
Cytokine therapy for hematological malignancies. Gan to kagaku ryoho. Cancer & chemotherapy, 1997, Volume: 24 Suppl 1 Topics: Antineoplastic Agents; Busulfan; Clinical Trials as Topic; Cytokines; Follow-Up Studies; Granulocyte	1997
Cancer chemotherapy in the elderly. Japanese journal of clinical oncology, 1998, Volume: 28, Issue:8 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aging; Anthraquinones; Antineoplastic Agents; Breast Neo	1998

Article	Year
Targeted Marrow Irradiation Intensification of Reduced-Intensity Fludarabine/Busulfan Conditioning for Allogeneic Hematopoietic Stem Cell Transplantation. Transplantation and cellular therapy, 2022, Volume: 28, Issue:7 Topics: Adolescent; Adult; Aged; Bone Marrow; Busulfan; Hematologic Neoplasms; Hematopoietic Stem Cell Trans	2022
Effects of combined test dose and therapeutic drug monitoring strategy in exposure-directed busulfan. Annals of hematology, 2023, Volume: 102, Issue:10 Topics: Busulfan; Cyclophosphamide; Drug Monitoring; Hematologic Neoplasms; Hematopoietic Stem Cell Transpla	2023
Analysis of glutathione S-transferase and cytochrome P450 gene polymorphism in recipients of dose-adjusted busulfan-cyclophosphamide conditioning. International journal of hematology, 2020, Volume: 111, Issue:1 Topics: Adult; Aged; Alleles; Area Under Curve; Busulfan; Cyclophosphamide; Cytochrome P-450 Enzyme System;	2020
Busulfan-cyclophosphamide versus cyclophosphamide-busulfan as conditioning regimen before allogeneic hematopoietic cell transplantation: a prospective randomized trial. Annals of hematology, 2021, Volume: 100, Issue:1 Topics: Adult; Aged; Busulfan; Chemical and Drug Induced Liver Injury; Cyclophosphamide; Drug Therapy, Combi	2021
Safety and Efficacy of Once-Daily Intravenous Busulfan in Allogeneic Transplantation: A Matched-Pair Analysis. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2018, Volume: 24, Issue:10 Topics: Adolescent; Adult; Busulfan; Disease-Free Survival; Female; Graft vs Host Disease; Hematologic Neopl	2018
Similar survival but increased toxicity with a sequential versus concurrent FluBu4 regimen. Bone marrow transplantation, 2018, Volume: 53, Issue:9 Topics: Allografts; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Disease-Free Survival; Female;	2018
Fludarabine with a higher versus lower dose of myeloablative timed-sequential busulfan in older patients and patients with comorbidities: an open-label, non-stratified, randomised phase 2 trial. The Lancet. Haematology, 2018, Volume: 5, Issue:11 Topics: Adolescent; Adult; Aged; Busulfan; Child; Comorbidity; Dose-Response Relationship, Drug; Drug Intera	2018
Renal dysfunction within 90 days of FluBu4 predicts early and late mortality. Bone marrow transplantation, 2019, Volume: 54, Issue:7 Topics: Acute Kidney Injury; Adolescent; Adult; Age Factors; Aged; Allografts; Antineoplastic Combined Chemo	2019
Thiotepa, Busulfan, and Fludarabine Conditioning Regimen in T Cell-Replete HLA-Haploidentical Hematopoietic Stem Cell Transplantation. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2019, Volume: 25, Issue:7 Topics: Adolescent; Adult; Aged; Busulfan; Cyclosporine; Disease-Free Survival; Female; Graft vs Host Diseas	2019
Association of Antiepileptic Medications with Outcomes after Allogeneic Hematopoietic Cell Transplantation with Busulfan/Cyclophosphamide Conditioning. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2019, Volume: 25, Issue:7 Topics: Adolescent; Adult; Aged; Allografts; Anticonvulsants; Busulfan; Child; Child, Preschool; Cyclophosph	2019
Phase II study of CD4+-guided pentostatin lymphodepletion and pharmacokinetically targeted busulfan as conditioning for hematopoietic cell allografting. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2013, Volume: 19, Issue:7 Topics: Acute Disease; Adult; Aged; Antineoplastic Agents; Busulfan; CD4 Lymphocyte Count; CD4-Positive T-Ly	2013
Palonosetron and dexamethasone for the prevention of nausea and vomiting in patients receiving allogeneic hematopoietic stem cell transplantation. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2014, Volume: 22, Issue:5 Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cyclophosphamide	2014
Prospective pharmacokinetic study of intravenous busulfan in hematopoietic stem cell transplantation in 25 children. Pediatric transplantation, 2014, Volume: 18, Issue:3 Topics: Adolescent; Area Under Curve; Asian People; Busulfan; Child; Child, Preschool; Female; Gas Chromatog	2014
Donor-derived natural killer cells infused after human leukocyte antigen-haploidentical hematopoietic cell transplantation: a dose-escalation study. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2014, Volume: 20, Issue:5 Topics: Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Child; Disease Progression; Female; Graft v	2014
Combination of linear accelerator-based intensity-modulated total marrow irradiation and myeloablative fludarabine/busulfan: a phase I study. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2014, Volume: 20, Issue:12 Topics: Adult; Aged; Allografts; Busulfan; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplant	2014
Reduced-toxicity conditioning with fludarabine, once-daily intravenous busulfan, and antithymocyte globulins prior to allogeneic stem cell transplantation: results of a multicenter prospective phase 2 trial. Cancer, 2015, Feb-15, Volume: 121, Issue:4 Topics: Adult; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Disease-Free	2015
Nonmyeloablative allogeneic hematopoietic stem cell transplant for the treatment of patients with hematologic malignancies using busulfan, fludarabine, and total body irradiation conditioning is effective in an elderly and infirm population. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2015, Volume: 21, Issue:1 Topics: Aged; Antineoplastic Agents; Busulfan; Cyclosporine; Female; Frail Elderly; Graft vs Host Disease; H	2015
Treosulfan-fludarabine-thiotepa conditioning before allogeneic haemopoietic stem cell transplantation for patients with advanced lympho-proliferative disease. A single centre study. Hematological oncology, 2016, Volume: 34, Issue:1 Topics: Adult; Bone Marrow Transplantation; Busulfan; Combined Modality Therapy; Disease-Free Survival; Fema	2016
Phase II Trial of Graft-versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide after Reduced-Intensity Busulfan/Fludarabine Conditioning for Hematological Malignancies. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2015, Volume: 21, Issue:5 Topics: Adolescent; Adult; Aged; Allografts; Busulfan; Child; Child, Preschool; Cyclophosphamide; Disease-Fr	2015
Once-daily i.v. BU-based conditioning regimen before allogeneic hematopoietic SCT: a study of influence of GST gene polymorphisms on BU pharmacokinetics and clinical outcomes in Chinese patients. Bone marrow transplantation, 2015, Volume: 50, Issue:5 Topics: Adolescent; Adult; Allografts; Asian People; Busulfan; China; Female; Glutathione Transferase; Hemat	2015
Preferential depletion of host over donor T cells through in vivo decay of active rabbit-anti-thymocyte globulin levels during reduced intensity conditioning. Bone marrow transplantation, 2015, Volume: 50, Issue:6 Topics: Adult; Aged; Animals; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Female; Follow-Up Studi	2015
Long-term outcome of HLA-haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion based on an FBCA conditioning regimen for hematologic malignancies. Bone marrow transplantation, 2015, Volume: 50, Issue:8 Topics: Adolescent; Adult; Allografts; Busulfan; Child; Cyclophosphamide; Disease-Free Survival; Female; Fol	2015
A Bortezomib-Based Regimen Offers Promising Survival and Graft-versus-Host Disease Prophylaxis in Myeloablative HLA-Mismatched and Unrelated Donor Transplantation: A Phase II Trial. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2015, Volume: 21, Issue:11 Topics: Adult; Bortezomib; Busulfan; Female; Follow-Up Studies; Graft vs Host Disease; Hematologic Neoplasms	2015
HLA-Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplant Cyclophosphamide after Busulfan-Containing Reduced-Intensity Conditioning. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2015, Volume: 21, Issue:9 Topics: Adolescent; Adult; Aged; Busulfan; Cyclophosphamide; Disease-Free Survival; Female; Hematologic Neop	2015
Phase I/II Trial of Dose-Escalated Busulfan Delivered by Prolonged Continuous Infusion in Allogeneic Transplant Patients. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2015, Volume: 21, Issue:12 Topics: Adult; Area Under Curve; Busulfan; Drug Administration Schedule; Female; Graft vs Host Disease; Hema	2015
A prospective multicenter study of unrelated bone marrow transplants using a reduced-intensity conditioning regimen with low-dose ATG-F. Bone marrow transplantation, 2016, Volume: 51, Issue:3 Topics: Adult; Aged; Allografts; Antilymphocyte Serum; Bone Marrow Transplantation; Busulfan; Chronic Diseas	2016
Posttransplantation cyclophosphamide for prevention of graft-versus-host disease after HLA-matched mobilized blood cell transplantation. Blood, 2016, Mar-17, Volume: 127, Issue:11 Topics: Adolescent; Adult; Aged; Allografts; Busulfan; Child; Child, Preschool; Cyclophosphamide; Disease-Fr	2016
Treosulfan/fludarabine as an allogeneic hematopoietic stem cell transplant conditioning regimen for high-risk patients. American journal of hematology, 2008, Volume: 83, Issue:9 Topics: Adolescent; Adult; Aged; Busulfan; Chemical and Drug Induced Liver Injury; Combined Modality Therapy	2008
Transplantation from matched siblings using once-daily intravenous busulfan/fludarabine with thymoglobulin: a myeloablative regimen with low nonrelapse mortality in all but older patients with high-risk disease. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2008, Volume: 14, Issue:8 Topics: Adolescent; Adult; Age Factors; Aged; Antibodies, Monoclonal; Antilymphocyte Serum; Busulfan; Graft	2008
Sirolimus, tacrolimus, and low-dose methotrexate as graft-versus-host disease prophylaxis in related and unrelated donor reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2008, Volume: 14, Issue:8 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Female; Graft Survival; Graft	2008
Pharmacokinetics of high-dose i.v. treosulfan in children undergoing treosulfan-based preparative regimen for allogeneic haematopoietic SCT. Bone marrow transplantation, 2008, Volume: 42 Suppl 2 Topics: Adolescent; Antineoplastic Agents, Alkylating; Busulfan; Child; Child, Preschool; Dose-Response Rela	2008
Busulfex (i.v. BU) and CY regimen before SCT: Japanese-targeted phase II pharmacokinetics combined study. Bone marrow transplantation, 2009, Volume: 43, Issue:8 Topics: Adolescent; Adult; Busulfan; Child; Child, Preschool; Cyclophosphamide; Female; Graft vs Host Diseas	2009
Improved nonrelapse mortality and infection rate with lower dose of antithymocyte globulin in patients undergoing reduced-intensity conditioning allogeneic transplantation for hematologic malignancies. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2009, Volume: 15, Issue:11 Topics: Adult; Aged; Animals; Anti-Infective Agents; Antilymphocyte Serum; Busulfan; Disease Susceptibility;	2009
Population pharmacokinetic study of a test dose oral busulfan in Japanese adult patients undergoing hematopoietic stem cell transplantation. Cancer chemotherapy and pharmacology, 2010, Volume: 65, Issue:6 Topics: Administration, Oral; Adolescent; Adult; Aged; Algorithms; Antineoplastic Agents, Alkylating; Area U	2010
Influence on Busilvex pharmacokinetics of clonazepam compared to previous phenytoin historical data. Anticancer research, 2010, Volume: 30, Issue:7 Topics: Adolescent; Adult; Alkylating Agents; Anticonvulsants; Busulfan; Clonazepam; Cyclophosphamide; Drug	2010
Conditioning with treosulfan and fludarabine followed by allogeneic hematopoietic cell transplantation for high-risk hematologic malignancies. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2011, Volume: 17, Issue:3 Topics: Adolescent; Adult; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined	2011
Phase I study of dose-escalated busulfan with fludarabine and alemtuzumab as conditioning for allogeneic hematopoietic stem cell transplant: reduced clearance at high doses and occurrence of late sinusoidal obstruction syndrome/veno-occlusive disease. Leukemia & lymphoma, 2010, Volume: 51, Issue:12 Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Busulf	2010
Influence of GST gene polymorphisms on the clearance of intravenous busulfan in adult patients undergoing hematopoietic cell transplantation. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2011, Volume: 17, Issue:8 Topics: Adolescent; Adult; Alkylating Agents; Busulfan; Cyclophosphamide; Drug Administration Schedule; Fema	2011
Treosulfan-based preparative regimens for allo-HSCT in childhood hematological malignancies: a retrospective study on behalf of the EBMT pediatric diseases working party. Bone marrow transplantation, 2011, Volume: 46, Issue:12 Topics: Adolescent; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Busul	2011
The effect of zinc sulfate in the prevention of high-dose chemotherapy-induced mucositis: a double-blind, randomized, placebo-controlled study. Hematological oncology, 2012, Volume: 30, Issue:1 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cyclophosphamide; Double-Blind Meth	2012
Accurate targeting of daily intravenous busulfan with 8-hour blood sampling in hospitalized adult hematopoietic cell transplant recipients. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2012, Volume: 18, Issue:2 Topics: Adult; Aged; Antineoplastic Agents; Busulfan; Cyclophosphamide; Female; Hematologic Neoplasms; Hemat	2012
Development and validation of a test dose strategy for once-daily i.v. busulfan: importance of fixed infusion rate dosing. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2012, Volume: 18, Issue:2 Topics: Adolescent; Adult; Aged; Busulfan; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplant	2012
A pilot pharmacologic biomarker study of busulfan and fludarabine in hematopoietic cell transplant recipients. Cancer chemotherapy and pharmacology, 2012, Volume: 69, Issue:1 Topics: Adult; Aged; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve;	2012
Maximally tolerated busulfan systemic exposure in combination with fludarabine as conditioning before allogeneic hematopoietic cell transplantation. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2012, Volume: 18, Issue:7 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Busulfan;	2012
Single-unit umbilical cord blood transplantation from unrelated donors in patients with hematological malignancy using busulfan, thiotepa, fludarabine and ATG as myeloablative conditioning regimen. Bone marrow transplantation, 2012, Volume: 47, Issue:10 Topics: Adolescent; Adult; Antilymphocyte Serum; Busulfan; Child; Child, Preschool; Cord Blood Stem Cell Tra	2012
Phase II prospective study of treosulfan-based reduced-intensity conditioning in allogeneic HSCT for hematological malignancies from 10/10 HLA-identical unrelated donor. Annals of hematology, 2012, Volume: 91, Issue:8 Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Pro	2012
Unmanipulated haploidentical bone marrow transplantation and posttransplantation cyclophosphamide for hematologic malignancies after myeloablative conditioning. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2013, Volume: 19, Issue:1 Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Agents; Bone Marrow Transplantation; Busulfan	2013
Dose intensification of busulfan in the preparative regimen is associated with improved survival: a phase I/II controlled, randomized study. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2013, Volume: 19, Issue:3 Topics: Administration, Oral; Aged; Busulfan; Drug Administration Schedule; Female; Graft vs Host Disease; H	2013
Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2002, Volume: 8, Issue:9 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Hematologic Neoplasms;	2002
Evaluation of safety and pharmacokinetics of administering intravenous busulfan in a twice-daily or daily schedule to patients with advanced hematologic malignant disease undergoing stem cell transplantation. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2002, Volume: 8, Issue:9 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cyclophosphamide; Drug Admini	2002
Intravenous versus oral busulfan as part of a busulfan/cyclophosphamide preparative regimen for allogeneic hematopoietic stem cell transplantation: decreased incidence of hepatic venoocclusive disease (HVOD), HVOD-related mortality, and overall 100-day mo Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2002, Volume: 8, Issue:9 Topics: Administration, Oral; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cyclophospham	2002
A phase II trial of liposomal busulphan as an intravenous myeloablative agent prior to stem cell transplantation: 500 mg/m(2) as a optimal total dose for conditioning. Bone marrow transplantation, 2002, Volume: 30, Issue:12 Topics: Adult; Age Factors; Busulfan; Child; Cyclophosphamide; Drug Administration Schedule; Drug Carriers;	2002
Lowered-intensity preparative regimen for allogeneic stem cell transplantation delays acute graft-versus-host disease but does not improve outcome for advanced hematologic malignancy. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2003, Volume: 9, Issue:3 Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Graft vs Host	2003
Fractionated TBI correlates with less T cell mixed chimerism but increased risk of relapse compared to busulphan in patients with haematological malignancies after allogeneic stem cell transplantation. Bone marrow transplantation, 2003, Volume: 32, Issue:5 Topics: Adolescent; Adult; Busulfan; Cell Lineage; Child; Child, Preschool; Dose Fractionation, Radiation; F	2003
Busulfan induces activin A expression in vitro and in vivo: a possible link to venous occlusive disease. Clinical pharmacology and therapeutics, 2003, Volume: 74, Issue:3 Topics: Activin Receptors; Activins; Antineoplastic Agents, Alkylating; Area Under Curve; Busulfan; Cell Lin	2003
I.V. busulfan in pediatrics: a novel dosing to improve safety/efficacy for hematopoietic progenitor cell transplantation recipients. Bone marrow transplantation, 2004, Volume: 33, Issue:10 Topics: Adolescent; Age Factors; Antineoplastic Agents, Alkylating; Area Under Curve; Body Weight; Busulfan;	2004
A prospective randomized trial comparing cyclosporine and short course methotrexate with cyclosporine and mycophenolate mofetil for GVHD prophylaxis in myeloablative allogeneic bone marrow transplantation. Bone marrow transplantation, 2004, Volume: 34, Issue:7 Topics: Adult; Antineoplastic Agents, Alkylating; Bone Marrow Transplantation; Busulfan; Cyclosporine; Drug	2004
Dose modification protocol using intravenous busulfan (Busulfex) and cyclophosphamide followed by autologous or allogeneic peripheral blood stem cell transplantation in patients with hematologic malignancies. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2004, Volume: 10, Issue:9 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Busulfan; Combi	2004
Dose-escalated treosulphan in combination with cyclophosphamide as a new preparative regimen for allogeneic haematopoietic stem cell transplantation in patients with an increased risk for regimen-related complications. Bone marrow transplantation, 2005, Volume: 35, Issue:3 Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Busu	2005
Cost effectiveness of day 5 G-CSF (Lenograstim) administration after PBSC transplantation: results of a SFGM-TC randomised trial. Bone marrow transplantation, 2005, Volume: 36, Issue:6 Topics: Adolescent; Adult; Aged; Blood Transfusion; Busulfan; Child; Child, Preschool; Cost-Benefit Analysis	2005
Successful engraftment following allogeneic stem cell transplantation in very high-risk patients with busulfan as a single agent. Haematologica, 2005, Volume: 90, Issue:8 Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Busulfan; Combined Modality Therapy; Hematologic Neo	2005
Comparable kinetics of myeloablation between fludarabine/full-dose busulfan and fludarabine/melphalan conditioning regimens in allogeneic peripheral blood stem cell transplantation. Bone marrow transplantation, 2006, Volume: 38, Issue:7 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Female; Graft Survival; Hematologic	2006
Case-control comparison of at-home to total hospital care for autologous stem-cell transplantation for hematologic malignancies. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Oct-20, Volume: 24, Issue:30 Topics: Adult; Aged; Anti-Bacterial Agents; Antibiotic Prophylaxis; Antineoplastic Agents, Alkylating; Busul	2006
Unmanipulated HLA 2-3 antigen-mismatched (haploidentical) stem cell transplantation using nonmyeloablative conditioning. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2006, Volume: 12, Issue:10 Topics: Adult; Antilymphocyte Serum; Bone Marrow; Busulfan; CD4 Lymphocyte Count; Combined Modality Therapy;	2006
F-ara-A pharmacokinetics during reduced-intensity conditioning therapy with fludarabine and busulfan. Bone marrow transplantation, 2007, Volume: 39, Issue:4 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Drug Interactions; Female; He	2007
Fludarabine vs cladribine plus busulfan and low-dose TBI as reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation: a prospective randomized trial. Bone marrow transplantation, 2007, Volume: 39, Issue:4 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Cladri	2007
Adult recipients of matched related donor blood cell transplants given myeloablative regimens including pretransplant antithymocyte globulin have lower mortality related to graft-versus-host disease: a matched pair analysis. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2007, Volume: 13, Issue:3 Topics: Adolescent; Adult; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Busulfan; G	2007
Allogeneic stem cell transplantation for patients with advanced hematological malignancies: comparison of fludarabine-based reduced intensity conditioning versus myeloablative conditioning. Journal of Korean medical science, 2007, Volume: 22, Issue:2 Topics: Adolescent; Adult; Aged; Busulfan; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplant	2007
Prospective phase II trial to evaluate the complications and kinetics of chimerism induction following allogeneic hematopoietic stem cell transplantation with fludarabine and busulfan. American journal of hematology, 2007, Volume: 82, Issue:10 Topics: Adult; Aged; Busulfan; Cyclosporine; Drug Therapy, Combination; Female; Graft Survival; Graft vs Hos	2007
Cyclophosphamide following targeted oral busulfan as conditioning for hematopoietic cell transplantation: pharmacokinetics, liver toxicity, and mortality. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2007, Volume: 13, Issue:7 Topics: Administration, Oral; Adolescent; Adult; Aged; Busulfan; Chemical and Drug Induced Liver Injury; Cyc	2007
Individual dose adjustment of oral busulfan using a test dose in hematopoietic stem cell transplantation. International journal of hematology, 2007, Volume: 86, Issue:3 Topics: Administration, Oral; Adult; Asian People; Busulfan; Female; Graft Survival; Hematologic Neoplasms;	2007
High busulfan exposure is associated with worse outcomes in a daily i.v. busulfan and fludarabine allogeneic transplant regimen. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2008, Volume: 14, Issue:2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Busulfan; Drug Monito	2008
Reduced-intensity conditioning allogeneic transplantation from unrelated donors: evaluation of mycophenolate mofetil plus cyclosporin A as graft-versus-host disease prophylaxis. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2008, Volume: 14, Issue:6 Topics: Adolescent; Adult; Antineoplastic Agents; Bone Marrow Transplantation; Busulfan; Combined Modality T	2008
In stem cell transplantation, by limiting the morbidity of graft-versus-host disease tolerance to myeloablative conditioning is improved. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2008, Volume: 14, Issue:6 Topics: Adolescent; Adult; Alemtuzumab; Antibiotic Prophylaxis; Antibodies, Monoclonal; Antibodies, Monoclon	2008
Phase I-II study of high-dose busulfan and cyclophosphamide followed by autologous peripheral blood stem cell transplantation for hematological malignancies: toxicities and hematopoietic recovery. Bone marrow transplantation, 1996, Volume: 18, Issue:1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Busulfan; Combined Modalit	1996
Veno-occlusive disease of the liver after busulfan, melphalan, and thiotepa conditioning therapy: incidence, risk factors, and outcome. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 1999, Volume: 5, Issue:5 Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Busulfan; Child; Child, Preschool; Cyclo	1999
Allogeneic peripheral blood stem cell transplantation in children with hematologic malignancies from HLA-matched siblings. Medical and pediatric oncology, 2000, Volume: 34, Issue:3 Topics: Adolescent; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Busul	2000
Acute safety and pharmacokinetics of intravenous busulfan when used with oral busulfan and cyclophosphamide as pretransplantation conditioning therapy: a phase I study. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2000, Volume: 6, Issue:5A Topics: Acetamides; Administration, Oral; Adult; Antineoplastic Combined Chemotherapy Protocols; Area Under	2000
Early full donor myeloid chimerism after reduced-intensity stem cell transplantation using a combination of fludarabine and busulfan. Haematologica, 2001, Volume: 86, Issue:10 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cell Lineage; Female; Graft Surviva	2001
Decreased transfusion requirements for patients receiving nonmyeloablative compared with conventional peripheral blood stem cell transplants from HLA-identical siblings. Blood, 2001, Dec-15, Volume: 98, Issue:13 Topics: Adult; Aged; Busulfan; Cyclophosphamide; Erythrocyte Transfusion; Female; Hematologic Neoplasms; Hem	2001
Conditioning therapy with intravenous busulfan and cyclophosphamide (IV BuCy2) for hematologic malignancies prior to allogeneic stem cell transplantation: a phase II study. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2002, Volume: 8, Issue:3 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Busulfan; Cyclophosphamide;	2002
Lorazepam for seizure prophylaxis during high-dose busulfan administration. Bone marrow transplantation, 2002, Volume: 29, Issue:12 Topics: Adolescent; Adult; Anticonvulsants; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemo	2002

Article	Year
GSTM1 and GSTT1 double null genotypes determining cell fate and proliferation as potential risk factors of relapse in children with hematological malignancies after hematopoietic stem cell transplantation. Journal of cancer research and clinical oncology, 2022, Volume: 148, Issue:1 Topics: Adolescent; Biomarkers, Tumor; Busulfan; Cell Line, Tumor; Cell Proliferation; Child; Child, Prescho	2022
HDAC inhibitors suppress protein poly(ADP-ribosyl)ation and DNA repair protein levels and phosphorylation status in hematologic cancer cells: implications for their use in combination with PARP inhibitors and chemotherapeutic drugs. Oncotarget, 2022, 10-14, Volume: 13 Topics: Antineoplastic Agents; Busulfan; Caspases; Chromatin; DNA; DNA Damage; DNA Repair; Hematologic Neopl	2022
Effective T-cell replete haploidentical stem cell transplantation for pediatric patients with high-risk hematologic disorders. European journal of haematology, 2023, Volume: 110, Issue:3 Topics: Busulfan; Child; Cyclophosphamide; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem	2023
Effective T-cell replete haploidentical stem cell transplantation for pediatric patients with high-risk hematologic disorders. European journal of haematology, 2023, Volume: 110, Issue:3 Topics: Busulfan; Child; Cyclophosphamide; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem	2023
Effective T-cell replete haploidentical stem cell transplantation for pediatric patients with high-risk hematologic disorders. European journal of haematology, 2023, Volume: 110, Issue:3 Topics: Busulfan; Child; Cyclophosphamide; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem	2023
Effective T-cell replete haploidentical stem cell transplantation for pediatric patients with high-risk hematologic disorders. European journal of haematology, 2023, Volume: 110, Issue:3 Topics: Busulfan; Child; Cyclophosphamide; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem	2023
A single-center experience of haploidentical stem cell transplantation in hematological malignancies. Turkish journal of medical sciences, 2023, Volume: 53, Issue:1 Topics: Busulfan; Child; Cyclophosphamide; Cyclosporine; Graft vs Host Disease; Hematologic Neoplasms; Hemat	2023
Intensified conditioning regimen with fludarabine combined with post-transplantation cyclophosphamide for haploidentical allogeneic hematopoietic stem cell transplantation in children with high-risk acute leukemia. Hematology (Amsterdam, Netherlands), 2023, Volume: 28, Issue:1 Topics: Acute Disease; Adult; Antilymphocyte Serum; Busulfan; Child; Cyclophosphamide; Cytarabine; Graft vs	2023
Factors predicting endocrine late effects in childhood cancer survivors from a Japanese hospital. Endocrine journal, 2020, Feb-28, Volume: 67, Issue:2 Topics: Adolescent; Adult; Antineoplastic Agents; Brain Neoplasms; Busulfan; Cancer Survivors; Child; Chroni	2020
When an HLA identical donor is not available in adults with hematological neoplasms: single-center comparison of single-unit cord blood transplantation and haploidentical-related PBSC transplantation with PTCy using a standardized conditioning platform (t Annals of hematology, 2020, Volume: 99, Issue:1 Topics: Adult; Aged; Allografts; Busulfan; Cord Blood Stem Cell Transplantation; Female; Hematologic Neoplas	2020
Acute toxicity and outcome among pediatric allogeneic hematopoietic transplant patients conditioned with treosulfan-based regimens. Pediatric hematology and oncology, 2020, Volume: 37, Issue:5 Topics: Adolescent; Antineoplastic Agents; Busulfan; Child; Child, Preschool; Cyclophosphamide; Disease-Free	2020
Busulfan clearance does not predict the development of hepatic veno-occlusive disease in patients undergoing hematopoietic stem cell transplantation. International journal of hematology, 2020, Volume: 112, Issue:2 Topics: Adolescent; Adult; Biomarkers; Busulfan; Child; Female; Hematologic Neoplasms; Hematopoietic Stem Ce	2020
UPLC-Tandem Mass Spectrometry for Quantification of Busulfan in Human Plasma: Application to Therapeutic Drug Monitoring. Scientific reports, 2020, 06-02, Volume: 10, Issue:1 Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Busulfan; Child; Child, Preschool; Chromatogra	2020
Pubertal outcomes of children transplanted with allogeneic stem cells after myeloablative total body irradiation or busulfan: Influence of age and sex is confirmed, while a role of chronic graft-versus-host disease in delayed puberty onset is revealed. Pediatric transplantation, 2020, Volume: 24, Issue:6 Topics: Adolescent; Busulfan; Child; Child, Preschool; Cyclophosphamide; Female; Graft vs Host Disease; Hema	2020
New dosing nomogram and population pharmacokinetic model for young and very young children receiving busulfan for hematopoietic stem cell transplantation conditioning. Pediatric blood & cancer, 2020, Volume: 67, Issue:10 Topics: Busulfan; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Monitoring; Female; Foll	2020
Allogeneic hematopoietic cell transplantation using fludarabine plus myeloablative busulfan and melphalan confers promising survival in high-risk hematopoietic neoplasms: a single-center retrospective analysis. Hematology (Amsterdam, Netherlands), 2021, Volume: 26, Issue:1 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Combined Modality	2021
Adding melphalan to fludarabine and a myeloablative dose of busulfan improved survival after allogeneic hematopoietic stem cell transplantation in a propensity score-matched cohort of hematological malignancies. Bone marrow transplantation, 2021, Volume: 56, Issue:7 Topics: Busulfan; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Hum	2021
Radiation-free myeloablative conditioning consisting of fludarabine added to full-dose busulfan and cyclophosphamide in single-unit cord blood transplantation for adults. European journal of haematology, 2021, Volume: 107, Issue:3 Topics: Adult; Blood Platelets; Busulfan; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Drug Admin	2021
Adverse Effects of Busulfan Plus Cyclophosphamide versus Busulfan Plus Fludarabine as Conditioning Regimens for Allogeneic Bone Marrow Transplantation. Asian Pacific journal of cancer prevention : APJCP, 2021, May-01, Volume: 22, Issue:5 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation	2021
Feasibility and Efficacy of a Pharmacokinetics-Guided Busulfan Conditioning Regimen for Allogeneic Stem Cell Transplantation with Post-Transplantation Cyclophosphamide as Graft-versus-Host Disease Prophylaxis in Adult Patients with Hematologic Malignancie Transplantation and cellular therapy, 2021, Volume: 27, Issue:11 Topics: Busulfan; Cyclophosphamide; Feasibility Studies; Graft vs Host Disease; Hematologic Neoplasms; Hemat	2021
Permanent diffuse alopecia after haematopoietic stem cell transplantation in childhood. Bone marrow transplantation, 2017, Volume: 52, Issue:7 Topics: Acute Disease; Adolescent; Adult; Alopecia; Busulfan; Child; Child, Preschool; Cross-Sectional Studi	2017
A Comparison of the Myeloablative Conditioning Regimen Fludarabine/Busulfan with Cyclophosphamide/Total Body Irradiation, for Allogeneic Stem Cell Transplantation in the Modern Era: A Cohort Analysis. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2018, Volume: 24, Issue:8 Topics: Adult; Aged; Busulfan; Cohort Studies; Cyclophosphamide; Female; Graft vs Host Disease; Hematologic	2018
Atypical cytological changes mimicking SIL of the uterine cervix in allogenic hematopoietic stem cell transplantation recipients treated with busulfan. Cancer cytopathology, 2019, Volume: 127, Issue:6 Topics: Adult; Busulfan; Cervix Uteri; Colposcopy; Diagnostic Errors; False Positive Reactions; Female; Foll	2019
Comparison of outcomes after two standards-of-care reduced-intensity conditioning regimens and two different graft sources for allogeneic stem cell transplantation in adults with hematologic diseases: a single-center analysis. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2013, Volume: 19, Issue:6 Topics: Adult; Aged; Antilymphocyte Serum; Busulfan; Cord Blood Stem Cell Transplantation; Cyclophosphamide;	2013
Pilot study of prophylactic ex vivo costimulated donor leukocyte infusion after reduced-intensity conditioned allogeneic stem cell transplantation. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2013, Volume: 19, Issue:7 Topics: Aged; Alemtuzumab; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Busulfan; Drug Administ	2013
National Institutes of Health classification for chronic graft-versus-host disease predicts outcome of allo-hematopoietic stem cell transplant after fludarabine-busulfan-antithymocyte globulin conditioning regimen. Leukemia & lymphoma, 2014, Volume: 55, Issue:5 Topics: Adolescent; Adult; Aged; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Busul	2014
Establishing a target exposure for once-daily intravenous busulfan given with fludarabine and thymoglobulin before allogeneic transplantation. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2013, Volume: 19, Issue:9 Topics: Administration, Intravenous; Adult; Aged; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy	2013
An anti-human thymocyte globulin-based reduced-intensity conditioning regimen is associated with a higher quality of life and lower organ toxicity without affecting lymphocyte reconstitution. PloS one, 2013, Volume: 8, Issue:9 Topics: Adolescent; Adult; Antilymphocyte Serum; Busulfan; Female; Graft vs Host Disease; Hematologic Neopla	2013
A conditioning platform based on fludarabine, busulfan, and 2 days of rabbit antithymocyte globulin results in promising results in patients undergoing allogeneic transplantation from both matched and mismatched unrelated donor. American journal of hematology, 2014, Volume: 89, Issue:1 Topics: Adult; Age Factors; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Busulfan;	2014
Evaluation of effects of busulfan and DMA on SOS in pediatric stem cell recipients. Pediatric blood & cancer, 2014, Volume: 61, Issue:2 Topics: Acetamides; Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemothera	2014
Fludarabine and exposure-targeted busulfan compares favorably with busulfan/cyclophosphamide-based regimens in pediatric hematopoietic cell transplantation: maintaining efficacy with less toxicity. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2014, Volume: 20, Issue:3 Topics: Adenoviridae Infections; Adolescent; Busulfan; Child; Child, Preschool; Cyclophosphamide; Female; Fo	2014
Antithymocyte globulin in reduced-intensity conditioning regimen allows a high disease-free survival exempt of long-term chronic graft-versus-host disease. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2014, Volume: 20, Issue:3 Topics: Adult; Aged; Antilymphocyte Serum; Antineoplastic Agents; Busulfan; Chronic Disease; Female; Graft v	2014
Predictors and impact of thirty-day readmission on patient outcomes and health care costs after reduced-toxicity conditioning allogeneic hematopoietic cell transplantation. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2014, Volume: 20, Issue:3 Topics: Adolescent; Adult; Aged; Busulfan; Cross Infection; Female; Graft vs Host Disease; Health Care Costs	2014
[The efficacy and safety of modified busulfan/fludarabine conditioning regimen in elderly or drug-intolerable patients with hematologic malignancies]. Zhonghua nei ke za zhi, 2013, Volume: 52, Issue:12 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Female; He	2013
Reduced intensity conditioning and oral care measures prevent oral mucositis and reduces days of hospitalization in allogeneic stem cell transplantation recipients. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2014, Volume: 22, Issue:8 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Cyclophosp	2014
Modified busulfan and cyclophosphamide conditioning regimen for allogeneic hematopoietic stem cell transplantation in the treatment of patients with hematologic malignancies. Transplantation proceedings, 2014, Volume: 46, Issue:5 Topics: Adolescent; Adult; Busulfan; Child; Cyclophosphamide; Female; Graft vs Host Disease; Hematologic Neo	2014
[Effect of BU and CY versus TBI and CY as conditioning regimens on the efficacy of haploidentical stem cell transplantation in patients with hematologic malignancy]. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2014, Volume: 35, Issue:6 Topics: Adolescent; Adult; Busulfan; Child; Child, Preschool; Cyclophosphamide; Female; Hematologic Neoplasm	2014
Busulfan dosing (Q6 or Q24) with adjusted or actual body weight, does it matter? Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2015, Volume: 21, Issue:6 Topics: Administration, Intravenous; Adult; Aged; Antineoplastic Agents, Alkylating; Area Under Curve; Body	2015
Palifermin reduces infection rate and hyperfibrinogenemia in patients treated with high-dose chemotherapy based on beam or BU-thiothepa. Bone marrow transplantation, 2014, Volume: 49, Issue:9 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carmustine; Cytar	2014
Lower dose of antithymocyte globulin does not increase graft-versus-host disease in patients undergoing reduced-intensity conditioning allogeneic hematopoietic stem cell transplant. Leukemia & lymphoma, 2015, Volume: 56, Issue:4 Topics: Adult; Aged; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Dose-Response Relationship, Drug	2015
A retrospective comparison of BU-fludarabine and BU-CY regimens in elderly patients or in patients with comorbidities who received unmanipulated haploidentical hematopoietic SCT. Bone marrow transplantation, 2015, Volume: 50, Issue:4 Topics: Adolescent; Adult; Allografts; Busulfan; Child; Child, Preschool; Comorbidity; Cyclophosphamide; Fem	2015
Clinical comparison of weight- and age-based strategy of dose administration in children receiving intravenous busulfan for hematopoietic stem cell transplantation. Pediatric transplantation, 2015, Volume: 19, Issue:3 Topics: Adolescent; Age Factors; Body Weight; Busulfan; Child; Child, Preschool; Cyclophosphamide; Female; F	2015
Economic and clinical aspects of intravenous versus oral busulfan in adult patients for conditioning prior to HSCT. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2015, Volume: 23, Issue:12 Topics: Administration, Intravenous; Administration, Oral; Adult; Aged; Busulfan; Drug Costs; Female; German	2015
Therapeutic drug monitoring for either oral or intravenous busulfan when combined with pre- and post-transplantation cyclophosphamide. Leukemia & lymphoma, 2016, Volume: 57, Issue:3 Topics: Adult; Aged; Busulfan; Cyclophosphamide; Drug Monitoring; Female; Graft vs Host Disease; Hematologic	2016
[Two Kinds of HLA-mismatched Allogeneic Hematopoictic Stem Cell Transplantation for Treatment of Hematologic Malignancies]. Zhongguo shi yan xue ye xue za zhi, 2016, Volume: 24, Issue:2 Topics: Antilymphocyte Serum; Busulfan; Cyclosporine; Graft vs Host Disease; Hematologic Neoplasms; Hematopo	2016
Intravenous Busulfan-Based Myeloablative Conditioning Regimens Prior to Hematopoietic Cell Transplantation for Hematologic Malignancies. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2016, Volume: 22, Issue:8 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool	2016
Haploidentical, unmanipulated G-CSF-primed peripheral blood stem cell transplantation for high-risk hematologic malignancies: an update. Bone marrow transplantation, 2016, Volume: 51, Issue:11 Topics: Adolescent; Adult; Busulfan; Child; Chimerism; Female; Graft vs Host Disease; Granulocyte Colony-Sti	2016
Allogeneic Hematopoietic Stem Cell Transplantation after Conditioning Regimens with Fludarabine/melphalan or Fludarabine/busulfan for Patients with Hematological Malignancies: A Single-center Analysis. Internal medicine (Tokyo, Japan), 2016, Volume: 55, Issue:13 Topics: Adult; Antineoplastic Agents; Busulfan; Drug Therapy, Combination; Female; Hematologic Neoplasms; He	2016
[Comparison of intensified myeloablative conditioning regime without antithymocytic globulin (ATG) with myeloablative conditioning regime for single-unit unrelated umbilical cord blood transplantation in hematological malignancies]. Zhonghua yi xue za zhi, 2016, Jul-26, Volume: 96, Issue:28 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; China; Cord Blood Stem	2016
A 5-day cytoreductive chemotherapy followed by haplo-identical hsct (FA5-BUCY) as a tumor-ablative regimen improved the survival of patients with advanced hematological malignancies. Oncotarget, 2016, Nov-29, Volume: 7, Issue:48 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Chemotherapy, Adjuvant;	2016
Impact of Human Leukocyte Antigen Allele Mismatch in Unrelated Bone Marrow Transplantation with Reduced-Intensity Conditioning Regimen. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2017, Volume: 23, Issue:2 Topics: Adolescent; Adult; Aged; Allografts; Bone Marrow Transplantation; Busulfan; Disease-Free Survival; F	2017
Mortality outcomes after busulfan-containing conditioning treatment and haemopoietic cell transplantation in patients with Gilbert's syndrome: a retrospective cohort study. The Lancet. Haematology, 2016, Volume: 3, Issue:11 Topics: Adult; Bilirubin; Busulfan; Cohort Studies; Cyclophosphamide; Dose-Response Relationship, Drug; Fema	2016
Population pharmacokinetics analysis of intravenous busulfan in Chinese patients undergoing hematopoietic stem cell transplantation. Clinical and experimental pharmacology & physiology, 2017, Volume: 44, Issue:5 Topics: Administration, Intravenous; Adolescent; Adult; Asian People; Busulfan; Child; Female; Hematologic N	2017
Incidence and risk factor of hemorrhagic cystitis after allogeneic transplantation with fludarabine, busulfan, and anti-thymocyte globulin myeloablative conditioning. Transplant infectious disease : an official journal of the Transplantation Society, 2017, Volume: 19, Issue:3 Topics: Antilymphocyte Serum; BK Virus; Busulfan; Case-Control Studies; Cystitis; Disease-Free Survival; Dru	2017
Outcomes following HSCT using fludarabine, busulfan, and thymoglobulin: a matched comparison to allogeneic transplants conditioned with busulfan and cyclophosphamide. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2008, Volume: 14, Issue:9 Topics: Acute Disease; Adolescent; Adult; Aged; Antibodies, Monoclonal; Antilymphocyte Serum; Busulfan; Chro	2008
Second malignancies in essential thrombocythemia (ET): a retrospective analysis of 331 patients with long-term follow-up from a single institution. Hematology (Amsterdam, Netherlands), 2008, Volume: 13, Issue:4 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alkylating Agents; Busulfan; Drug Therapy, Combination;	2008
A single apheresis procedure in the donor may be enough to complete an allograft using the "Mexican method" of non-ablative allografting. Blood transfusion = Trasfusione del sangue, 2009, Volume: 7, Issue:2 Topics: Anemia, Aplastic; Antineoplastic Combined Chemotherapy Protocols; Blood Component Removal; Blood Don	2009
Reduced-intensity conditioning using fludarabine with either antithymocyte globulin and BU, or low-dose TBI allowing allogeneic hematopoietic SCT. Bone marrow transplantation, 2010, Volume: 45, Issue:1 Topics: Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Clinical Protocols; Female; Hematologic Neo	2010
A comparative study of outcomes of idarubicin- and etoposide-intensified conditioning regimens for allogeneic peripheral blood stem cell transplantation in patients with high-risk acute leukemia. Acta pharmacologica Sinica, 2009, Volume: 30, Issue:10 Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Aspergillus; Busulfan; China; Combine	2009
Reduced-intensity conditioning hematopoietic stem cell transplantation in patients over 60 years: hematologic malignancy outcomes are not impaired in advanced age. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2010, Volume: 16, Issue:6 Topics: Age Factors; Aged; Aging; Blood Donors; Busulfan; Disease-Free Survival; Female; Graft vs Host Disea	2010
Frequency, risk factors, and outcome of acute kidney injury following bone marrow transplantation at Dr Shariati Hospital in Tehran. Iranian journal of kidney diseases, 2010, Volume: 4, Issue:1 Topics: Acute Kidney Injury; Adolescent; Adult; Bone Marrow Transplantation; Busulfan; Child; Child, Prescho	2010
Therapeutic drug monitoring for busulfan in plasma during conditioning chemotherapy for autologous stem cell transplantation in relapsed primary cerebral lymphoma. Therapeutic drug monitoring, 2010, Volume: 32, Issue:3 Topics: Behavior Therapy; Busulfan; Cyclophosphamide; Drug Monitoring; Half-Life; Hematologic Neoplasms; Hem	2010
Allogeneic hematopoietic stem-cell transplantation in patients with hematologic malignancies after dose-escalated treosulfan/fludarabine conditioning. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Jul-10, Volume: 28, Issue:20 Topics: Adolescent; Adult; Busulfan; Drug Therapy, Combination; Feasibility Studies; Female; Hematologic Neo	2010
Reduced-intensity conditioning with Fludarabin, oral Busulfan, and thymoglobulin allows long-term disease control and low transplant-related mortality in patients with hematological malignancies. Experimental hematology, 2010, Volume: 38, Issue:12 Topics: Adolescent; Adult; Antibodies, Monoclonal; Antilymphocyte Serum; Busulfan; Female; Graft vs Host Dis	2010
Association of busulfan and cyclophosphamide conditioning with sleep disorders after hematopoietic stem cell transplantation. Acta haematologica, 2010, Volume: 124, Issue:2 Topics: Adult; Busulfan; Cyclophosphamide; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoiet	2010
Influence of comorbidities on transplant outcomes in patients aged 50 years or more after myeloablative conditioning incorporating fludarabine, BU and ATG. Bone marrow transplantation, 2011, Volume: 46, Issue:8 Topics: Age Factors; Aged; Antilymphocyte Serum; Busulfan; Comorbidity; Disease-Free Survival; Female; Graft	2011
Increasing the dose intensity of the conditioning regimen prior to allogeneic hematopoietic stem cell transplant: the role of pharmacokinetic monitoring. Leukemia & lymphoma, 2010, Volume: 51, Issue:12 Topics: Busulfan; Dose-Response Relationship, Drug; Graft vs Host Disease; Hematologic Neoplasms; Hematopoie	2010
Weight-based strategy of dose administration in children using intravenous busulfan: clinical and pharmacokinetic results. Pediatric blood & cancer, 2012, Volume: 58, Issue:1 Topics: Adolescent; Antineoplastic Agents, Alkylating; Area Under Curve; Body Weight; Busulfan; Child; Child	2012
[Umbilical cord blood cell transplantation from an unrelated donor: dual transplantation]. Methods and findings in experimental and clinical pharmacology, 2010, Volume: 32 Suppl A Topics: Adolescent; Adult; Busulfan; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Disease-Free Su	2010
Idarubicin-intensified BUCY2 regimens may lower relapse rate and improve survival in patients undergoing allo-SCT for high-risk hematological malignancies: a retrospective analysis. Bone marrow transplantation, 2012, Volume: 47, Issue:2 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Chimerism; Combined Mod	2012
Long-term results of allogeneic hematopoietic stem cell transplantation after reduced-intensity conditioning with busulfan, fludarabine, and antithymocyte globulin. Neoplasma, 2011, Volume: 58, Issue:5 Topics: Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Cohort Studies; Drug Therapy, Combination;	2011
Low incidence and severity of oral mucositis in allogeneic stem cell transplantation after conditioning with treosulfan and fludarabine. European journal of haematology, 2012, Volume: 88, Issue:1 Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Busulfan; Female; Hematologic Neoplasms;	2012
Toll-like 4 receptor variant, Asp299Gly, and reduced risk of hemorrhagic cystitis after hematopoietic stem cell transplantation. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2012, Volume: 18, Issue:6 Topics: Adolescent; Adult; Age Factors; Antineoplastic Agents; Busulfan; Child; Child, Preschool; Cystitis;	2012
Pharmacokinetic-directed high-dose busulfan combined with cyclophosphamide and etoposide results in predictable drug levels and durable long-term survival in lymphoma patients undergoing autologous stem cell transplantation. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2012, Volume: 18, Issue:8 Topics: Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cohort Studies; Cyclophosphamide; Drug Adm	2012
The toxicity and efficacy of donor lymphocyte infusions given after reduced-intensity conditioning allogeneic stem cell transplantation. Blood, 2002, Nov-01, Volume: 100, Issue:9 Topics: Adult; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neo	2002
A limited sampling strategy for pharmacokinetic directed therapy with intravenous busulfan. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2002, Volume: 8, Issue:11 Topics: Antineoplastic Agents, Alkylating; Area Under Curve; Busulfan; Clinical Trials, Phase II as Topic; D	2002
Graft-versus-host disease following allogeneic transplantation from HLA-identical sibling with antithymocyte globulin-based reduced-intensity preparative regimen. Blood, 2003, Jul-15, Volume: 102, Issue:2 Topics: Acute Disease; Adolescent; Adult; Antilymphocyte Serum; Busulfan; Chronic Disease; Disease Progressi	2003
Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. Blood, 2003, Jul-15, Volume: 102, Issue:2 Topics: Aged; Bone Marrow Transplantation; Busulfan; Cause of Death; Cyclosporine; Female; Graft vs Host Dis	2003
Impact of graft-versus-host disease in reduced-intensity stem cell transplantation (RIST) for patients with haematological malignancies. British journal of haematology, 2003, Volume: 121, Issue:2 Topics: Acute Disease; Adolescent; Adult; Aged; Busulfan; Chronic Disease; Cladribine; Cyclophosphamide; Dis	2003
Re: intravenous versus oral busulfan--perhaps not as different as suggested. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2003, Volume: 9, Issue:4 Topics: Administration, Oral; Antineoplastic Agents, Alkylating; Area Under Curve; Busulfan; Hematologic Neo	2003
Decreased transfusion requirements in patients given stem cell allografts using a non-myeloablative conditioning regimen: a single institution experience. Hematology (Amsterdam, Netherlands), 2003, Volume: 8, Issue:3 Topics: Adolescent; Adult; Busulfan; Child; Child, Preschool; Cyclophosphamide; Cyclosporine; Erythrocyte Tr	2003
[Treatment of malignant hematologic diseases by peripheral blood stem cell transplantation combined with halotype lymphocyte infusion]. Zhongguo shi yan xue ye xue za zhi, 2003, Volume: 11, Issue:3 Topics: Adult; Busulfan; Child; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Female;	2003
Intravenous busulfan in pretransplant chemotherapy: bioavailability and patient benefit. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2003, Volume: 9, Issue:11 Topics: Administration, Oral; Antineoplastic Agents, Alkylating; Biological Availability; Busulfan; Hematolo	2003
Reduced-intensity conditioning with busulfan and fludarabine with or without antithymocyte globulin in HLA-identical sibling transplantation--a retrospective analysis. Bone marrow transplantation, 2004, Volume: 33, Issue:5 Topics: Acute Disease; Adult; Aged; Antilymphocyte Serum; Busulfan; Chronic Disease; Combined Modality Thera	2004
Disturbances of growth and endocrine function after busulphan-based conditioning for haematopoietic stem cell transplantation during infancy and childhood. Bone marrow transplantation, 2004, Volume: 33, Issue:10 Topics: Adolescent; Antineoplastic Agents, Alkylating; Body Height; Busulfan; Calcium; Child; Child, Prescho	2004
Low transplant-related mortality with allogeneic stem cell transplantation in elderly patients. Bone marrow transplantation, 2004, Volume: 34, Issue:2 Topics: Aged; Busulfan; Feasibility Studies; Female; Graft Survival; Graft vs Host Disease; Hematologic Neop	2004
Conditioning regimens including high-dose busulfan cause a high incidence of transplant-related mortality after myeloablative stem cell transplantation. Chemotherapy, 2004, Volume: 50, Issue:4 Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Busulfan; Female; Graft vs Host Disease; Healt	2004
Pharmacokinetics and individualized dose adjustment of intravenous busulfan in children with advanced hematologic malignancies undergoing allogeneic stem cell transplantation. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2004, Volume: 10, Issue:11 Topics: Adolescent; Antineoplastic Agents, Alkylating; Busulfan; Case-Control Studies; Child; Child, Prescho	2004
Comparison of ARF after myeloablative and nonmyeloablative hematopoietic cell transplantation. American journal of kidney diseases : the official journal of the National Kidney Foundation, 2005, Volume: 45, Issue:3 Topics: Acute Kidney Injury; Adolescent; Adult; Aged; Busulfan; Cohort Studies; Comorbidity; Cyclophosphamid	2005
An evaluation of busulfan pharmacokinetics in patients undergoing hematopoietic stem cell transplantation. Japanese journal of clinical oncology, 2005, Volume: 35, Issue:7 Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemot	2005
Successful engraftment following allogeneic stem cell transplantation in very high-risk patients with busulfan as a single agent. Haematologica, 2005, Volume: 90, Issue:8 Topics: Antineoplastic Agents, Alkylating; Busulfan; Combined Modality Therapy; Hematologic Neoplasms; Human	2005
Extracorporeal photo-chemotherapy for graft-versus-host disease. Haematologica, 2005, Volume: 90, Issue:8 Topics: Busulfan; Graft vs Host Disease; Hematologic Neoplasms; Humans; Leukemia; Lymphoma, Non-Hodgkin; Pho	2005
Extracorporeal chemophototherapy for the treatment of graft-versus-host disease: hematologic consequences of short-term, intensive courses. Haematologica, 2005, Volume: 90, Issue:8 Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Busulfan; Female; Graft vs Host Disease; Hematologic	2005
[Allogeneic blood stem cell transplantation in high-risk patients after conditioning with treosulfan and fludarabine]. Deutsche medizinische Wochenschrift (1946), 2005, Sep-23, Volume: 130, Issue:38 Topics: Adult; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Busulfan; Disease-Free Survival; Do	2005
Cataracts among cancer survivors. American journal of clinical oncology, 2005, Volume: 28, Issue:6 Topics: Adrenal Cortex Hormones; Adult; Aging; Bone Marrow Transplantation; Breast Neoplasms; Busulfan; Cata	2005
Risk factor analysis for thrombotic microangiopathy after reduced-intensity or myeloablative allogeneic hematopoietic stem cell transplantation. American journal of hematology, 2006, Volume: 81, Issue:7 Topics: Adolescent; Adult; Aged; Busulfan; Disease-Free Survival; Evaluation Studies as Topic; Female; Graft	2006
Hepatic injury following reduced intensity unrelated cord blood transplantation for adult patients with hematological diseases. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2006, Volume: 12, Issue:12 Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Bacterial Infections; Busulfan; Chemical and Drug In	2006
[Allogenic transplantation of hemopoietic stem cells in low-intensity regimes in patients with hematological malignancies]. Terapevticheskii arkhiv, 2007, Volume: 79, Issue:7 Topics: Acute Disease; Adolescent; Adult; Aged; Busulfan; Female; Graft vs Host Disease; Hematologic Neoplas	2007
Predictive factors for outcomes after reduced intensity conditioning hematopoietic stem cell transplantation for hematological malignancies: a 10-year retrospective analysis from the Société Française de Greffe de Moelle et de Thérapie Cellulaire. Experimental hematology, 2008, Volume: 36, Issue:5 Topics: Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Child; Child, Preschool; Disease-Free Survi	2008
Characterization of acute graft-versus-host disease following reduced-intensity stem-cell transplantation from an HLA-identical related donor. American journal of hematology, 2008, Volume: 83, Issue:8 Topics: Acute Disease; Adrenal Cortex Hormones; Adult; Aged; Antilymphocyte Serum; Busulfan; Cladribine; Dis	2008
Unrelated donor bone marrow transplantation without T cell depletion using a chemotherapy only condition regimen. Low incidence of failed engraftment and severe acute GVHD. Bone marrow transplantation, 1996, Volume: 17, Issue:4 Topics: Actuarial Analysis; Acute Disease; Adult; Anti-Infective Agents; Bone Marrow Transplantation; Busulf	1996
High incidence of chronic GVHD after primary allogeneic peripheral blood stem cell transplantation in patients with hematologic malignancies. Bone marrow transplantation, 1996, Volume: 17, Issue:4 Topics: Adult; Busulfan; Chimera; Cyclophosphamide; Female; Graft vs Host Disease; Hematologic Neoplasms; He	1996
A pilot study of busulfan and melphalan as preparatory regimen prior to allogeneic bone marrow transplantation in refractory or relapsed hematological malignancies. Bone marrow transplantation, 1996, Volume: 18, Issue:3 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Female	1996
Allogeneic BMT for haematological disorders: single centre experience of University Hospital Bratislava. Bone marrow transplantation, 1998, Volume: 22 Suppl 4 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busu	1998
Impaired plasma antioxidative defense and increased nontransferrin-bound iron during high-dose chemotherapy and radiochemotherapy preceding bone marrow transplantation. Free radical biology & medicine, 2000, Mar-15, Volume: 28, Issue:6 Topics: Allantoin; Antineoplastic Agents; Antioxidants; Bone Marrow Transplantation; Busulfan; Combined Moda	2000
Cardiac systolic function before and after hematopoietic stem cell transplantation. Bone marrow transplantation, 2000, Volume: 26, Issue:2 Topics: Adolescent; Adult; Anthracyclines; Breast Neoplasms; Busulfan; Female; Follow-Up Studies; Hematologi	2000
Individualizing high-dose oral busulfan: prospective dose adjustment in a pediatric population undergoing allogeneic stem cell transplantation for advanced hematologic malignancies. Bone marrow transplantation, 2000, Volume: 26, Issue:5 Topics: Administration, Oral; Adolescent; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemoth	2000
Idarubicin intensified BUCY2 regimen in allogeneic unmanipulated transplant for high-risk hematological malignancies. Leukemia, 2000, Volume: 14, Issue:12 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool	2000
Immune reconstitution following allogeneic stem cell transplantation in recipients conditioned by low intensity vs myeloablative regimen. Bone marrow transplantation, 2001, Volume: 28, Issue:3 Topics: Adolescent; Adult; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Busulfan; C	2001
Busulfan levels are influenced by prior treatment and are associated with hepatic veno-occlusive disease and early mortality but not with delayed complications following marrow transplantation. Bone marrow transplantation, 2001, Volume: 27, Issue:11 Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols	2001
Improved clinical outcome of paediatric bone marrow recipients using a test dose and Bayesian pharmacokinetic individualization of busulfan dosage regimens. Bone marrow transplantation, 2001, Volume: 28, Issue:8 Topics: Adolescent; Alkylating Agents; Area Under Curve; Bayes Theorem; Bone Marrow Transplantation; Busulfa	2001

busulfan and Hematologic Malignancies

Research Excerpts

Research

Studies (198)

Authors

Clinical Trials (22)

Trial Overview

Trial Outcomes

Non-Relapse Mortality Rate (NRM)

Overall Survival

Overall Survival

Number of Participants With 1 Year Mortality Unrelated to TMI

Number of Participants With Grade 4 TMI Toxicity

Time to Neutrophil and Platelet Engraftment in Patients With Hematologic Malignancies

The Cumulative Incidence of Chronic GVHD Requiring Systemic Immune Suppression up to 1 Year After Stem Cell Infusion

The Cumulative Incidence of Grade II-IV Acute GVHD up to Day 100 After Stem Cell Infusion

The Percentage Donor Engraftment up to Day 30 Post Stem Cell Infusion

The Non-relapse Mortality, Progression-free and Overall Survival up to 1 Year After Stem Cell Infusion

Capacity of Test Dosing of Busulfan That Would Result in the Desired Area Under the Curve Concentration Exposure of Patients Receiving a Full-dose Busulfan Regimen

Number of Participants With Dose Limiting Toxicities (DLTs)

Overall Survival

Three-year Relapse-free Survival (RFS) Rate at the Maximum Tolerated Dose Identified During Phase I of the Trial (Target AUC 6912)

Incidence of DNA Chimerism in Patients Between One Month Post Transplant

Incidence of Graft vs Host Disease in Patients Between One Month and Two Years Post Transplant

Chronic GVHD Requiring Systemic Immunosuppressive Treatment

Disease-free Survival

Donor Engraftment

Graft Failure

Non-relapse Mortality

Overall Survival

Persistent or Recurrent Malignancy After HCT

Grades II-IV and III-IV Acute GVHD

Hematologic Recovery

To Compare the Relapse Rate at 1 Year of Patients With Myeloid Malignancies Receiving Each Treatment

Disease Free Survival

Maximum Tolerated Dose

Overall Survival

Non-relapse Mortality

Severe Venous Occlusive Disease (VOD)/ Sinusoidal Obstructive Syndrome (SOS)

Reviews

Trials

Other Studies